



**NATIONAL CANCER REGISTRY**

**Division of the National Health Laboratory Service**



**health**

Department:  
Health  
**REPUBLIC OF SOUTH AFRICA**

---

# EKURHULENI POPULATION- BASED CANCER REGISTRY 2024 REPORT

---

Johannesburg, South Africa, March 2026

**Copyright © 2026**

**Citation:**

**National Cancer Registry, South Africa. Ekurhuleni Population-Based Cancer Registry  
2024 Report. [www.ncr.ac.za](http://www.ncr.ac.za).**

**Compiled by:**

Babongile Ndlovu (Epidemiologist)

Dr Judith Mwansa-Kambafwile (Senior Epidemiologist)

Dr Mazvita Muchengeti (Head of Department, Senior Epidemiologist)

**Ekurhuleni Population-Based Cancer Registry Surveillance Officers:**

Nelisiwe Fakude

Simphiwe Javu

Londiwe Nyembe

Sphiwe Mpangani

Phelade Kale

Clarence Sibiya

Nomthandazo Dube

Ekurhuleni Population-Based Cancer Registry

National Cancer Registry, National Health Laboratory Service

1 Modderfontein Road, Sandringham

Johannesburg

South Africa

2131

Tel: +27 11 555 0548

Fax to email: +27 11 386 6516

Website: [www.ncr.ac.za](http://www.ncr.ac.za)

## **DISCLAIMER**

This report includes all reported cancer cases for Ekurhuleni residents diagnosed from 1<sup>st</sup> January 2024 to 31<sup>st</sup> December 2024 as recorded in the Ekurhuleni population-based cancer registry (EPBCR). The information reflects the data at the time of closing the 2024 database for cleaning and analysis on the 6<sup>th</sup> of March 2026. The EPBCR continues to receive and collect additional data; therefore, the data may be updated as and when necessary. Special requests for data should be directed to the NCR administrator, Ms Hellen Mathabatha, [HellenM@nicd.ac.za](mailto:HellenM@nicd.ac.za).

## TABLE OF CONTENTS

DISCLAIMER .....	iii
TABLE OF CONTENTS.....	iv
LIST OF TABLES .....	v
<b>LIST OF FIGURES .....</b>	<b>v</b>
<b>LIST OF APPENDICES .....</b>	<b>v</b>
FOREWORD .....	viii
EXECUTIVE SUMMARY .....	ix
INTRODUCTION .....	1
METHODS .....	3
<b>Data sources.....</b>	<b>3</b>
<b>Data collection and processes.....</b>	<b>6</b>
<b>Confidentiality.....</b>	<b>8</b>
<b>Statistical analysis .....</b>	<b>9</b>
RESULTS .....	10
<b>Overall cancer incidence .....</b>	<b>10</b>
<b>Comparison of top cancer incidence across the years 2017- 2024.....</b>	<b>16</b>
<b>Childhood cancer incidence .....</b>	<b>18</b>
<b>Data Quality Indicators.....</b>	<b>19</b>
DISCUSSION .....	21
CONCLUSION.....	23
ACKNOWLEDGEMENTS .....	23
REFERENCES .....	26
APPENDICES .....	28

## LIST OF TABLES

Table 1: Summary Statistics For All Cancers In Men, EPBCR 2024 .....	11
Table 2: Summary Statistics For All Cancers In Women, EPBCR 2024 .....	12
Table 3: Childhood Cancers, EPBCR 2024.....	18
Table 4: Percentage Of Cases Morphologically Verified (Mv), Diagnosed Clinically Or Diagnosed By Death Certificate Only (Dco), EPBCR 2024 .....	19

## LIST OF FIGURES

Figure 1: Ekurhuleni Population-Based Cancer Registry Data Sources Map, 31 December 2024.....	5
Figure 2: Ekurhuleni Population-Based Cancer Registry Data Flow Diagram, 2017-2024.....	7
Figure 3: Percentage Of Cancer Cases By Sex And Population Group, EPBCR 2024.....	10
Figure 4: Frequency Of Most Common Cancers In Males, EPBCR 2024 .....	13
Figure 5: Age Standardised Incidence Rates For Most Common Cancers In Males, EPBCR 2024.....	13
Figure 6: Frequency Of Most Common Cancers In Females, EPBCR 2024.....	14
Figure 7: Age-Standardised Incidence Rates For Common Cancers In Females, EPBCR 2024 .....	14
Figure 8: ASR For Top 5 Cancers In Men By Population Group, EPBCR 2024.....	15
Figure 9: ASR For Top 5 Cancers In Women By Population Group, EPBCR 2024 .....	15
Figure 10: ASRS For Most Common Cancers In Men, 2017-2024 .....	16
Figure 11: ASRS For Most Common Cancers In Women, 2017-2024 .....	17
Figure 12: Number Of Cancer Cases Reported By Year And Sex, EPBCR 2017-2024.....	17

## LIST OF APPENDICES

Appendix 1: List Of Data Sources .....	28
Appendix 2: South African Cancer Notification Form.....	30
Appendix 3: Tables Of Incidence By Site, Sex, Age Group And Population, 2024 .....	31

## **ACRONYMS AND ABBREVIATIONS**

AFCRN	: African Cancer Registry Network
ASR	: Age-Standardised Incidence Rate
BCC	: Basal Cell Carcinoma
CIDERU	: Cancer & Infectious Diseases Epidemiology Research Unit
CIDERU	: Cancer and Infectious Disease Epidemiology Research Unit
CNS	: Central Nervous System
COVID-19	: Coronavirus Disease 2019
DHA	: Department of Home Affairs, South Africa
DoH	: Department of Health, South Africa
ECCR	: Eastern Cape Cancer Registry
EPBCR	: Ekurhuleni Population-Based Cancer Registry
GICR	: Global Initiative for Cancer Registry Development
IACR	: International Association of Cancer Registries
IARC	: International Agency for Research on Cancer
ICCC	: International Classification of Childhood Cancer
ICDO-3	: International Classification of Diseases for Oncology Third Edition
INCTR	: International Network for Cancer Treatment and Research
KZN PBCR	: KwaZulu-Natal Population-Based Cancer Registry
KZN	: KwaZulu-Natal
LMIC	: Low- or Middle-Income Country
NCDs	: Non-Communicable Disease
NCR	: National Cancer Registry, South Africa
NHLS	: National Health Laboratory Service

PBCR : Population-Based Cancer Registry

POPI Act : Protection of Personal Information Act, South Africa

SA : South Africa

SACCSG : South African Children's Study Cancer Group

SAMRC : South African Medical Research Council

SAOC : South African Oncology Consortium

STATSSA : Statistics, South Africa

UICC : Union for International Cancer Control

UP : University of Pretoria

WHO : World Health Organization


WSP : World Standard Population

## **FOREWORD**

It gives me great pleasure to make public the 2024 annual report of the Ekurhuleni Population-Based Cancer Registry (EPBCR).

The current report on the EPBCR culminates from support from the National Institute for Communicable Diseases, the National Health Laboratory Service, and the work of the National Cancer Registry (NCR). This is the eighth report to be produced for the EPBCR; previous reports have covered the years 2017 to 2023. While this report provides essential information for healthcare planning locally, the vision for the EPBCR has always been to reach benchmark international standards to report South Africa's cancer incidence rates to the International Agency for Research on Cancer (IARC). With each successive year of operations, the EPBCR has achieved progressively better data quality.

In the 2025/2026 financial year, access to healthcare facilities for surveillance officers has remained stable, supporting continued progress in cancer case finding. The challenges posed by load shedding, which previously disrupted registry operations through power outages and network connectivity failures at healthcare facilities, have substantially lessened. However, new operational challenges have emerged, notably the cyberattack on the National Health Laboratory Service and the fragmentation of patient records arising from the rollout of a new unified patient identification system, both of which have affected case confirmation and data completeness. Despite these setbacks, I commend the EPBCR staff and stakeholders for their continued dedication and resilience in sustaining cancer surveillance under difficult circumstances.



Dr Mazvita Muchengeti

**(Head of the Department, National Cancer Registry)**

Date: 31 March 2026

## **EXECUTIVE SUMMARY**

The 2024 cancer incidence report from the Ekurhuleni Population-Based Cancer Registry (EPBCR) marks the eighth year of comprehensive cancer surveillance since the registry's establishment in 2017, following the enactment of Regulation No. 380 of the National Health Act, which mandates cancer as a reportable disease in South Africa.

In 2024, a total of 4,914 new cancer cases were registered, the highest annual total in the registry's eight-year history and a 23% increase from 3,978 cases in 2023, with 2,066 (42.0%) in males and 2,848 (58.0%) in females. The most common cancers in males were prostate, colorectal, and lung cancers, and in females, cervical, breast, and colorectal cancers. Prostate cancer recorded its highest ASR over the reporting period at 46.91 per 100,000, while cervical (ASR: 35.31) and breast (ASR: 37.96) cancers continued to dominate in women. The White population recorded the highest ASRs across most cancer types, with the exception of cervical and vulvar cancers, where Black women showed higher rates, reflecting persistent inequalities in healthcare access and the ongoing impact of HPV and HIV co-infection. Fifty-one childhood cancer cases were registered, accounting for 1% of all cancers, with lymphoma and leukaemia being the most common.

Data quality improved notably, with 96.6% of cases morphologically verified, up from 88.7% in 2023. However, a cyberattack on the National Health Laboratory Service disrupted data workflows, and the rollout of a new patient identification system caused record fragmentation, both contributing to delays in case confirmation. The 2024 total therefore likely modestly underestimates true incidence.

Key institutional milestones include the concurrent publication of the KZN PBCR's second annual report and the concept notes for registries in the Western Cape and within SAPRIN nodes have been developed, aiming to extend surveillance beyond incidence to outcomes, survival, and risk factors. Sustained expansion of the national PBCR network require formal government funding commitment as it is the most critical outstanding barrier to equitable, comprehensive cancer surveillance in South Africa.

## **INTRODUCTION**

Cancer is an escalating public health concern in South Africa, with approximately 90,000 new cases estimated annually, driven by population ageing, urbanisation, lifestyle transitions, and persistent disparities in access to early detection and treatment (1–6). However, reliable population-level data on cancer incidence, treatment outcomes, and survivorship remain critically limited throughout the country (7).

Cancer surveillance in South Africa has historically relied on the NCR's pathology-based registry, which records only laboratory-confirmed diagnoses (8). This approach underestimates the true cancer burden by excluding cancers diagnosed clinically, radiologically, or at death (9). Population-based cancer registries (PBCRs) address this limitation by systematically capturing all cancer cases from all available sources within defined populations and are therefore the gold standard for estimating true cancer incidence and informing cancer prevention and control policy (10).

The NCR is mandated to establish a network of PBCRs across South Africa (11). Site selection has been guided by a deliberate sampling strategy to ensure that, collectively, the registries capture the full demographic, geographic, and epidemiological diversity of South Africa's population. The Ekurhuleni PBCR (EPBCR), established in 2017, was the first site, selected because it uniquely represents all four major South African population groups (Black, White, Coloured, and Asian/Indian). However, minority populations such as the Asian/Indian and Coloured communities remain numerically small, resulting in unstable cancer incidence estimates. This informed the selection of subsequent registries: the KwaZulu-Natal PBCR (established 2023) oversamples the Asian/Indian population and covers high HIV-prevalence and rural areas. Additional registries are planned for the Western Cape, which will leverage the Provincial Health Data Centre (12) to construct a virtual cancer cohort, and for Limpopo, designated as an NHI pilot site.

Most ambitiously, the NCR has developed a concept for embedding PBCRs within the South African Population Research Infrastructure Network (SAPRIN), a national platform of seven Health and Demographic Surveillance System nodes monitoring over 700,000 individuals with longitudinal demographic, vital events, risk factor, and health service access data (13). Integrating cancer surveillance within SAPRIN would enable the study of cancer as a

continuum, linking diagnoses to HIV status, socioeconomic circumstances, treatment pathways, survival outcomes, and comorbidities, evidence currently unavailable from any existing registry in South Africa.

The EPBCR continues to upscale its skills and international engagement in preparation for expanded national responsibilities. Staff members have completed modules from the IARC/GICR e-learning (14), which provides internationally recognised training in cancer registration standards, and the NCR continues to advocate for all registry personnel and stakeholders to pursue this qualification. The registry manager and a surveillance officer presented the EPBCR's work at the IACR 2025 conference in Izmir, Turkey, and both the EPBCR and KZN PBCR showcased their registry results at the 2025 AFCRN meeting in Abuja, Nigeria. The EPBCR also contributes its data to international databases, supporting comparative analyses and external quality benchmarking.

The 2024 reporting period presented operational challenges. The cyberattack on the National Health Laboratory Service disrupted laboratory data workflows, requiring manual retrospective data capture and slowing case confirmation. Concurrently, at facility level, a new unified patient identification system caused record fragmentation, complicating patient tracking. These challenges have temporarily affected the completeness of the 2024 dataset, and the registry is actively working to resolve outstanding cases. Notwithstanding these difficulties, the EPBCR has maintained its relationships with key data sources, including public hospitals, private sector partners SAOC and Icon Oncology, and the NHLS, and the overall trajectory of the registry in terms of data volume, quality, and institutional stability remains positive.

This is the eighth annual cancer incidence report for the EPBCR, accounting for all reported cancers diagnosed in 2024.

## **METHODS**

The EPBCR employs cancer registration guidelines and strategies developed by the International Association of Cancer Registries (IACR), the International Agency for Research on Cancer (IARC) and the African Cancer Registry Network (AFCRN). The EPBCR employs both passive (receives reports from facilities) and active surveillance (sends surveillance officers to facilities collect information from different sources), collecting data on all cancer patients residing in Ekurhuleni metropolitan municipality diagnosed by clinical, radiological, pathology or any other means of investigation.

### **Data sources**

#### **i. Government and Private Hospitals/Healthcare Facilities**

The EPBCR has multiple data sources. The data sources extend beyond the borders of the Ekurhuleni metropolitan municipality due to the nature of the South African healthcare referral system. The municipalities do not often have all levels of care (level 1: Primary healthcare clinic, Community healthcare centre, District hospital, level 2: Regional hospital, level 3: Provincial tertiary hospital, and level 4: Central hospital and Specialised hospital) within its borders (15). Therefore, patients may be referred out of the municipality to access further diagnosis and management. Secondly, South African patients are a highly mobile population and have the freedom to choose the healthcare facility they prefer, which may not necessarily be within the borders of the district in which they reside.

In addition to the public healthcare facilities, South Africa also has a large and well-resourced private healthcare industry. Sixteen per cent of the South African population has medical health insurance and is thus able to access healthcare in private healthcare facilities. Therefore, to obtain complete reporting from the Ekurhuleni District's population, the EPBCR also collects data from private hospitals, and clinicians in independent private practice (See Appendix 1 for a comprehensive list of data sources).

#### **ii. Laboratories, Oncology Networks and Associations**

SA has an expansive network of both public and private laboratories. An estimated 80% of the SA's population is serviced by NHLS, which has over 200 laboratories in nine provinces of SA (16). The other estimated 20% of the population is covered

by private laboratories which include but are not limited to Ampath, Pathcare and Lancet laboratories. Both public and private laboratories send electronic reports of patients diagnosed with cancer to the NCR's national pathology surveillance programme. The surveillance officers use all the pathology reports received from laboratories together with other data tools (medical files, hospital register, pharmacy list etc.) to identify, trace and register patients from Ekurhuleni metropolitan municipality into the EPBCR.

In addition, Icon Oncology and the South African Oncology Consortium (SAOC) report their relevant data for residents of Ekurhuleni to the NCR. The surveillance officers use these data sources to consolidate missing information for patients already registered in the EPBCR database or to trace and notify the patient in conjunction with other data tools from different data sources. Finally, surveillance officers use hospital registers, patient files and mortuary records to identify new patients not already recorded in an existing database available to the NCR.

**iii. The Hospice**

The surveillance officers visit hospices at regular intervals to consolidate information missing for patients already registered from other data sources such as hospitals, as well as to report any new patients identified.

**iv. Vital Statistics (Death Registration)**

The Department of Home Affairs (DHA) is the custodian of vital statistics for SA. Statistics South Africa (STATS SA) also has cleaned vital statistics data for South Africans that can be used to consolidate vital status (i.e. dead/alive) in the EPBCR. However, STATS SA is unable to legally share identifiable patient-level data with other official organisations. To compensate for the challenge, the surveillance officers visit the mortuaries within healthcare facilities to trace and report cases of cancer for patients who may have been missed while alive.

Figure 1 below illustrates the spatial distribution of the data sources for EPBCR as of 31 December 2024.




Figure 1: Ekurhuleni population-based cancer registry data sources map, 31 December 2024

## Data collection and processes

The EPBCR uses both active and passive methods of case finding.

Active case finding:

- The surveillance officers visit healthcare facilities to review electronic and or physical records of patients such as patient files, admission registers, pathology reports, radiology reports, death registers, outpatient registers, pharmacy registers and clinicians' statistical records to notify confirmed cancer cases on the cancer notification forms.

Passive case finding:

- As mentioned above, both the Icon Oncology and the South African Oncology Consortium (SAOC) passively provide data to the NCR for the Ekurhuleni district.
- Data is also extracted from the national pathology registry (both public and private sector data) to supplement the EPBCR dataset.

Inclusion criteria for both active and passive case-finding methods:

- All confirmed cancer cases, in persons who are residents of the Ekurhuleni metropolitan municipality, diagnosed from 1<sup>st</sup> January to 31 December of the relevant year must be reported to the registry.
- Cancer cases include:
  - Cases considered malignant in the morphology section of the International Classification of Diseases for Oncology (ICD-O); behaviour code-3 are reported to the registry.
  - Cancers in metastatic sites (for example, lymph nodes) are registered with the primary tumour site topography. If this is not known, it is registered as an unknown primary site.

The surveillance officers extract data/variables required (See Appendix 2: South African Cancer Registration Form) from data sources such as medical records and code the cancer diagnosis according to the International Classification of Diseases for Oncology 3<sup>rd</sup> edition (ICDO-3) for topography and morphology. A pathology report, where available, is filed with the corresponding notification form. Reports are filed according to the date and facility of diagnosis.

The files are then captured onto the RedCap system. The NCR uses REDCap instead of the IARC-recommended CanReg system because CanReg did not meet the current data processing requirements, such as large storage capacity, simultaneous multiple users and virtual network use.




Figure 2: Ekurhuleni Population-Based Cancer Registry data flow diagram, 2017-2024

The captured files are sent to the surveillance manager for quality assurance and quality control. The surveillance manager uses both the physical notification forms and electronic records on Redcap for each cancer case to check for duplicates, completeness, and consistency. The files are stored in a locked cabinet for 20 years as per the South Africa Protection of Personal Information Act (POPI Act ) before they are permanently destroyed (17). The complete, quality-assured dataset is extracted per year (1<sup>st</sup> January to 31<sup>st</sup> December for each year) for cleaning and analysis using Stata software. The analyzed data is then used for annual incidence reports, teaching/training, and research purposes. Figure 2, above illustrates the data processing and flow for the EPBCR.

## **Confidentiality**

The NCR adheres to the NHLS, the IARC/IACR guidelines and the POPI Act to ensure the preservation of privacy during the EPBCR surveillance process (17). Request to use de-identified individual-level EPBCR data by entities/individuals is sought in writing to the NCR and applying for data through the NHLS Academic Affairs and Research Management System (<https://aarms.nhls.ac.za/>). Ethics approval is required before data is granted. Cancer statistics are released in an aggregated format through the annual reports published on the NCR website <https://www.nicd.ac.za/centres/national-cancer-registry/>.

## Statistical analysis

The results are presented as:

- the number of new cancer cases,
- the percentage of all new cancer cases,
- Age-standardised incidence rate (ASR) per 100,000 and
- The lifetime risk

The results are further stratified by:

- sex (Male and Female),
- population group (Black, White, Asian and Coloured) and
- age groups (5-year interval, e.g.0-4 years, 5-9, 10-14, etc.).

For age standardization, the Segi World Standard Population (WSP) is used as per international cancer registration norms. STATS SA 2024 mid-year population data for Ekurhuleni metropolitan municipality was used as a denominator.

The calculation methods are as follows:

$$\text{Crude} = \frac{\text{Number of new cases}}{\text{Mid-year population}} \times 100,000$$

$$\text{WSP weighting} = \frac{\text{WSP (for each age group)}}{\text{Total WSP for all age groups}} \times 100,000$$

$$\text{ASR} = \text{Crude} \times \text{WSP weighting}$$

## RESULTS

### Overall cancer incidence

A total of 4,914 cancer cases were registered by the EPBCR for the year 2024, with 2066 cases (42.0%) occurring in males and 2848 (58.0%) occurring in females. Benign growths, in-situ lesions and cancers of unknown behaviour were excluded from the data collection and analysis.

Figure 3 below shows the percentage of cancer cases diagnosed in 2024 by sex and population group. Sixty-six per cent of cases were diagnosed among the Black population, 30% among the White population, while 2% was diagnosed among the Coloured and Asian population groups, respectively.




Figure 3: Percentage of cancer cases by sex and population group, EPBCR 2024.

Tables 1 and 2 illustrate a detailed tabulation of cases registered in 2024 for males and females. The tables show the total number of cases registered, crude rates per 100 000 population, age-adjusted incidence rates per 100 000 population, cumulative and lifetime risk for each cancer. Appendix tables further elaborate on these data by demonstrating frequency, age-standardised and age-specific incidence rates by population group and sex.

Table 1: Summary statistics for all cancers in Men, EPBCR 2024

<b>SITE</b>	<b>N*</b>	<b>CRUDE RATE</b>	<b>ASR</b>	<b>CUM RISK 0-74</b>	<b>LIFETIME RISK 0-74</b>
All sites	2066	107,29	107,32	12	8
All sites but skin	1935	100,43	100,55	11	9
Prostate	884	45,91	46,91	6	17
Colorectal	156	8,10	7,97	1	104
Primary site unknown	84	4,36	4,37	1	192
Lung	78	4,05	4,08	0	207
Non Hodgkin lymphoma	64	3,32	3,07	0	315
Melanoma	53	2,75	2,82	0	359
SCC of skin	51	2,65	2,61	0	336
Oesophagus	47	2,44	2,38	0	358
Leukaemia	46	2,39	2,38	0	433
Bladder	43	2,23	2,37	0	352
Stomach	45	2,34	2,32	0	404
BCC	44	2,28	2,31	0	433
Penis	38	1,97	1,91	0	413
Skin other	36	1,87	1,79	0	639
Kaposi Sarcoma	34	1,77	1,58	0	579
Liver & Bile duct	27	1,40	1,36	0	672
Naso-Oropharynx	24	1,25	1,27	0	718
Larynx	24	1,25	1,26	0	594
Pancreas	23	1,19	1,15	0	793
Hodgkin lymphoma	23	1,19	1,14	0	1017
Kidney	20	1,04	1,09	0	875
Myeloma	21	1,09	1,04	0	922
Other specified	20	1,04	0,98	0	1086
Brain, CNS	19	0,99	0,97	0	1092
Breast	17	0,88	0,90	0	791
Anus	19	0,99	0,90	0	1029
Ill defined	17	0,88	0,82	0	987
Testis	18	0,93	0,80	0	1630
Tongue	14	0,73	0,76	0	947
Connective tissue	16	0,83	0,75	0	1643
Thyroid	10	0,52	0,58	0	1530
Salivary gland	10	0,52	0,52	0	2291
Mouth	9	0,47	0,51	0	1518
Haematology other	9	0,47	0,47	0	2667
Mesothelioma	7	0,36	0,35	0	1499
Endocrine	5	0,26	0,28	0	3339
Eye	3	0,16	0,18	0	7491
Lip	3	0,16	0,15	0	5953
Small intestine	2	0,10	0,11	0	9662
Bone	2	0,10	0,09	0	10205
Burkitt lymphoma	1	0,05	0,05	0	31251

Table 2: Summary statistics for all cancers in Women, EPBCR 2024

SITE	N*	CRUDE RATE	ASR	CUM RISK 0-74	LIFETIME RISK 0-74
All sites	2848	137,75	139,77	14	7
All sites but skin	2763	133,59	134,41	14	7
Breast	782	37,82	37,96	4	24
Cervix	799	38,65	35,31	4	26
Colorectal	152	7,35	8,15	1	106
Uterus	138	6,67	7,53	1	97
Primary site unknown	128	6,19	6,49	1	143
Vulva	110	5,32	4,64	0	244
Non Hodgkin lymphoma	71	3,43	3,58	0	310
Lung	43	2,08	2,57	0	375
Ovary	49	2,37	2,48	0	388
SCC of skin	39	1,89	2,34	0	789
Melanoma	38	1,84	2,06	0	517
Leukaemia	35	1,69	2,02	0	572
Oesophagus	32	1,55	1,85	0	517
BCC	30	1,45	1,79	0	715
Anus	36	1,74	1,60	0	669
Other specified	28	1,35	1,41	0	616
Stomach	23	1,11	1,30	0	652
Liver & Bile duct	21	1,02	1,30	0	658
Bladder	20	0,97	1,17	0	822
Skin other	16	0,77	1,11	0	1202
Myeloma	19	0,92	1,09	0	737
Thyroid	24	1,16	1,02	0	849
Pancreas	17	0,82	0,99	0	734
Brain, CNS	18	0,87	0,95	0	1069
Connective tissue	17	0,82	0,93	0	1391
Haematology other	13	0,63	0,83	0	1176
Kaposi Sarcoma	21	1,02	0,78	0	1524
Vagina	14	0,68	0,76	0	1556
Hodgkin lymphoma	15	0,73	0,71	0	1693
Ill defined	15	0,73	0,70	0	1054
Mesothelioma	12	0,58	0,67	0	1178
Kidney	8	0,39	0,42	0	1628
Naso-Oropharynx	9	0,44	0,41	0	2146
Larynx	8	0,39	0,40	0	2039
Tongue	7	0,34	0,38	0	1584
Eye	7	0,34	0,35	0	2711
Endocrine	6	0,29	0,35	0	4684
Mouth	5	0,24	0,32	0	3045
Small intestine	6	0,29	0,31	0	2248
Salivary gland	6	0,29	0,29	0	2858
Bone	6	0,29	0,28	0	4033
Placenta	4	0,19	0,14	0	9091
Lip	1	0,05	0,03	0	42554

Figure 4-7 below illustrates the frequency and age-standardised incidence rates of the most common cancers registered in the EPBCR in 2024 for males and females. Prostate cancer was by far the most common cancer amongst men with 884 cases and an ASR of 46.91/100 000 population. Amongst women, breast cancer was leading with 782 new cases reported with an ASR of 37.96/100 000. Figures 8 and 9 illustrate the top 5 cancers ASRs by population group. In males, the White population group had the highest ASR in prostate cancer followed Black, Asian then coloured. In females, the White population group had the highest ASR in breast cancer, followed by Asian, Black then Coloured.




Figure 4: Frequency of most common cancers in males, EPBCR 2024




Figure 5: Age Standardised Incidence Rates for most common cancers in males, EPBCR 2024




Figure 6: Frequency of most common cancers in females, EPBCR 2024




Figure 7: Age-standardised incidence rates for common cancers in females, EPBCR 2024




Figure 8: ASR for top 5 cancers in men by population group, EPBCR 2024




Figure 9: ASR for top 5 cancers in women by population group, EPBCR 2024

## Comparison of top cancer incidence across the years 2017- 2024

Figures 10 and 11 show a comparison of ASRs for common cancers from 2017 to 2024 by sex. In men (Figure 10), prostate cancer consistently recorded the highest ASRs across all years, remaining the dominant cancer site throughout the reporting period. Notably, the 2024 ASR for prostate cancer rose sharply to approximately 46 per 100,000, representing the highest rate observed in the entire 2017–2024 period and a marked increase from the 2023 estimate of approximately 19 per 100,000. Colorectal and lung cancers in men recorded comparatively lower and more stable ASRs across the period, both ranging between approximately 3 and 10 per 100,000, with modest increases observed in 2024 relative to 2023.




Figure 10: ASRs for most common cancers in men, 2017-2024

In women (Figure 11), breast cancer remained the most commonly diagnosed cancer throughout the reporting period, with the 2024 ASR reaching approximately 37 per 100,000; the highest recorded over the eight-year period. Cervical cancer was the second most common cancer in women, with its 2024 ASR of approximately 35 per 100,000 representing a substantial increase from 2023 (approximately 14 per 100,000) and the highest rate seen across the period. Colorectal cancer in women continued to record the lowest ASRs among the top three cancers, remaining relatively stable and below 10 per 100,000, with a slight increase in 2024 compared to 2023.




Figure 11: ASRs for most common cancers in women, 2017-2024

Figure 12 shows the total number of cancer cases reported to the EPBCR from 2017 to 2024, disaggregated by sex. Over the eight-year reporting period, a general upward trend in the total number of cancer cases was observed, with some fluctuation across years. The highest number of cases was recorded in 2024, with a total of 4,914 cases. This represents an increase from 3,978 total cases recorded in 2023, continuing the recovery and upward trajectory seen after the notable dip in 2019, which reflects the impact of disruptions to health services and cancer registration during that period.




Figure 12: Number of Cancer cases reported by year and sex, EPBCR 2017-2024

### Childhood cancer incidence

Table 3 below shows cancers in children aged 0-19 years in the Ekurhuleni area. A total of 51 childhood cancer cases were registered in 2024, an increase from 37 cases in 2023, accounting for approximately 1% of all cancers registered. Males outnumbered females with an overall male-to-female ratio of 9:1. The highest number of cases recorded in the 15–19 age group (16 cases) and the lowest in the 0–4 age group (8 cases). Lymphoma was the most frequently diagnosed cancer with 10 cases (ASR: 7.74 per million), followed by leukaemia with 6 cases (ASR: 4.37 per million), and CNS neoplasms and soft tissue sarcomas each recording 4 cases. The overall ASR for all childhood cancer sites was 39.43 per million.

Table 3: Childhood cancers, EPBCR 2024

Cancer	Number of cases						Rates per Million Age-Specific Rates					Crude	ASR	LCL	UCL
	Age 0-4	Age 5-9	Age 10-14	Age 15-19	All Ages	M/F ratio	Age 0-4	Age 5-9	Age 10-14	Age 10-14					
Leukaemia	0	0	4	2	6	1	0	0	13	7	4,75	4,37	1,60	9,62	
Lymphoma	1	3	0	6	10	2	3	10	0	20	7,91	7,74	3,70	14,27	
CNS Neoplasms	1	2	1	0	4		3	6	3	0	3,17	3,22	0,87	8,23	
Neuroblastoma	1	0	0	0	1		3	0	0	0	0,79	0,89	0,02	4,69	
Nephroblastoma - Wilms Tumour	1	0	2	0	3	2	3	0	6	0	2,37	2,33	0,48	6,87	
Soft Tissue Sarcomas	0	2	2	0	4	1	0	6	6	0	3,17	3,05	0,83	7,87	
Germ Cell Tumours	0	1	0	1	2		0	3	0	3	1,58	1,54	0,19	5,62	
Primary site unknown	0	0	0	1	1		0	0	0	3	0,79	0,74	0,02	4,27	
Other, specified	4	4	6	6	20	3	12	13	19	20	15,83	15,55	9,48	24,06	
<b>All sites</b>	<b>8</b>	<b>12</b>	<b>15</b>	<b>16</b>	<b>51</b>	<b>9</b>	<b>24</b>	<b>39</b>	<b>48</b>	<b>53</b>	<b>40,36</b>	<b>39,43</b>	<b>17,19</b>	<b>91,34</b>	

## Data Quality Indicators

### a) Basis of Diagnosis

Table 4 demonstrates the proportion of cases that were morphologically verified (MV) (histology, cytology or bone marrow aspirate and trephine), diagnosed by clinical means or registered from death certificate-only information (DCO). Four thousand nine hundred and nine (4909) of the registered 4914 cases had a method of diagnosis known. The majority of cases (96.6%) were morphologically verified, reflecting a high level of diagnostic quality and pathological confirmation within the registry. Clinically diagnosed cases accounted for 2.9% of all registrations, while death certificate only cases were minimal at 0.4%, indicating that very few cases were registered solely on the basis of death certificates. The low DCO proportion and high MV percentage are positive indicators of data quality and completeness for the 2024 reporting period.

Table 4: Percentage of cases Morphologically Verified (MV), diagnosed clinically or diagnosed by Death Certificate Only (DCO), EPBCR 2024

Cancer Site	Cases		Basis of Diagnosis		
	No. of Cases	% Total	DCO	Clinical	MV
Anus	55	1,12	0	1,8	98,2
BCC	74	1,51	0	2,7	97,3
Bladder	63	1,28	0	4,8	95,2
Bone	8	0,16	0	0	100
Brain, CNS	37	0,75	0	8,1	91,9
Breast	797	16,24	0,4	0,9	98,5
Burkitt lymphoma	1	0,02	0	0	100
Cervix	798	16,26	0,3	2,9	96,7
Colorectal	307	6,25	0	2,3	97,4
Connective tissue	33	0,67	0	0	100
Endocrine	11	0,22	0	0	100
Eye	10	0,20	0	0	100
Haematology other	22	0,45	0	0	100
Hodgkin lymphoma	38	0,77	0	0	100
Ill defined	32	0,65	0	6,2	93,8
Kaposi Sarcoma	55	1,12	0	1,8	98,2
Kidney	28	0,57	0	3,6	96,4
Larynx	32	0,65	0	0	100
Leukaemia	81	1,65	0	1,2	98,8
Lip	4	0,08	0	0	100
Liver & Bile duct	48	0,98	0	8,3	91,7

Lung	121	2,46	2,5	6,6	90,9
Melanoma	91	1,85	0	0	100
Mesothelioma	19	0,39	0	5,3	94,7
Mouth	14	0,29	7,1	0	92,9
Myeloma	40	0,81	0	0	100
Naso-Oropharynx	33	0,67	0	0	100
Non Hodgkin lymphoma	135	2,75	0	3	97
Oesophagus	79	1,61	1,3	3,8	94,9
Other specified	48	0,98	0	6,2	93,8
Ovary	49	1,00	0	12,2	87,8
Pancreas	40	0,81	0	7,5	92,5
Penis	38	0,77	0	0	100
Placenta	4	0,08	0	0	100
Primary site unknown	212	4,32	1,4	3,8	94,8
Prostate	884	18,01	0,6	5	94,5
SCC of skin	90	1,83	0	0	100
Salivary gland	16	0,33	0	0	100
Skin other	52	1,06	0	1,9	98,1
Small intestine	8	0,16	0	0	100
Stomach	67	1,36	0	0	98,5
Testis	18	0,37	0	0	100
Thyroid	34	0,69	0	5,9	94,1
Tongue	21	0,43	0	0	100
Uterus	138	2,81	0	2,9	97,1
Vagina	14	0,29	0	0	100
Vulva	110	2,24	0	1,8	98,2
<b>All Sites</b>	<b>4,909</b>	<b>100</b>	<b>0,4</b>	<b>2,9</b>	<b>96,6</b>

#### **b) Primary site unknown (PSU)**

There were 212 cases of cancer (4.3%) reported where the primary site was unspecified or uncertain from the available documentation. The ASRs of PSU were 4,37 and 6.49 /100 000 in men and women, respectively.

#### **c) Age unknown**

There was no record with unknown age.

## DISCUSSION

This report marks the eighth year of cancer incidence reporting from the EPBCR, detailing cancer cases diagnosed during 2024. A total of 4,914 cancer cases were registered, with 2,066 (42.0%) in males and 2,848 (58.0%) in females; the highest annual total since the registry's establishment in 2017 and a notable increase from 3,978 cases in 2023.

The most common cancers among males in 2024 were prostate, colorectal, lung, non-Hodgkin lymphoma, and melanoma. Among females, the leading cancers were breast, cervix, colorectal, uterus, and vulva. These patterns remain consistent with previous reporting years, suggesting that the underlying risk factor profile and demographic determinants of cancer incidence in Ekurhuleni have not shifted significantly.

Prostate cancer remained the most common cancer in men with 884 cases and an ASR of 46.91 per 100,000; the highest recorded over the 2017–2024 period. Among women, cervical cancer (799 cases; ASR: 35.31) and breast cancer (782 cases; ASR: 37.96) continued to dominate. The sustained high burden of cervical cancer reflects the persistent impact of HPV and HIV co-infection, particularly among Black South African women, where high-risk HPV strains remain highly prevalent (18–20). Despite available HPV vaccination and screening programmes, coverage and uptake remain suboptimal in public sector settings, pointing to the need for strengthened prevention strategies (21).

As in previous years, the White population recorded the highest ASRs for most cancer types, with the exception of cervical and vulvar cancers, where Black women showed higher rates. This pattern likely reflects inequalities in healthcare access, with the majority of White patients covered by medical aid and therefore able to access private diagnostic and treatment services more readily (7). A large proportion of Black patients depend on the public health system, where resource constraints and complex referral pathways contribute to diagnostic delays and poorer outcomes (22). Higher ASRs among White patients for cancers such as prostate, breast, and colorectal may also partly reflect better case ascertainment through private sector data sources incorporated via SAOC and Icon Oncology partnerships.

Fifty-one childhood cancer cases were registered in 2024, up from 37 in 2023, accounting for approximately 1% of all cancers — consistent with prior years. This proportion likely

underestimates the true paediatric cancer burden given capacity constraints within specialised oncology services. Lymphoma was the most frequent diagnosis (10 cases; ASR: 7.74 per million), followed by leukaemia (6 cases; ASR: 4.37 per million), with an overall childhood cancer ASR of 39.43 per million. Wide confidence intervals reflect small case numbers and highlight the need for dedicated paediatric cancer surveillance capacity.

The morphological verification rate improved markedly to 96.6% in 2024 from 88.7% in 2023, reflecting the EPBCR's continued investment in active case finding and strong data source relationships. DCO cases remained minimal at 0.4% and clinically diagnosed cases accounted for 2.9%; cases that would not be captured by the NCR's pathology-based system, underscoring the added value of population-based registration. Primary site unknown cases accounted for 4.3%, a marginal improvement from 4.6% in 2023, and remains an area for ongoing improvement.

The reporting periods for 2023 and 2024 were significantly disrupted by a cyberattack on the NHLS, which forced laboratory services to be outsourced to private practices and resulted in records being returned in manual formats rather than digital entries. This created a stark contrast between the two years, where the 2023 data reflects an artificial dip due to missing digital captures evidenced by Ekurhuleni having 383 cases against a typical volume of over 2,500 cases. Consequently, the 2024 data shows an apparent spike, such as the cervical cancer ASR jumping from 14 to 35 per 100,000, which is a technical anomaly caused by the retrospective back-capturing of these manual records rather than a true clinical surge. Cervical cancer data shows the most variance in this regard because it relies heavily on high-volume clinic screening results that were delayed by the slow process of manual data entry into TrakCare. Facility data collection was further destabilized by the abrupt stoppage of the hospital record systems and a fire at one of the regional hospitals, which significantly hindered reporting efforts in that area. These challenges, further compounded by synchronization failures in the new unified patient identification system, highlight the vulnerability of cancer surveillance to infrastructure disruptions. To correct for these discrepancies, a future re-analysis of the 2023 baseline is planned once the full data supplement from the private sector is integrated to accurately reflect the true incidence trends.

The KZN PBCR concurrently has published its second annual report, reflecting growing operational maturity. Concept notes for Western Cape and SAPRIN registries have been developed.

## **CONCLUSION**

The 2024 EPBCR report documents 4,914 cancer cases, the highest annual total in the registry's eight-year history, reflecting both a genuine increase in cancer burden and continued strengthening of case ascertainment. Cancer patterns by sex and population group remain consistent with prior years, with prostate cancer dominating in men and cervical and breast cancers leading in women. Persistent disparities between population groups underscore the ongoing relevance of equity-focused cancer control strategies in South Africa.

The high MV rate of 96.6% affirms the registry's data quality standards. However, the NHLS cyberattack and patient record fragmentation have introduced uncertainty into the completeness of the 2024 dataset, and the registry is actively working to resolve outstanding cases. These disruptions are an important reminder of the fragility of surveillance systems dependent on a single data infrastructure.

Looking ahead, the EPBCR remains committed to leading a robust, nationally representative PBCR network. Realising this vision will require formal government funding commitment to complement the institutional progress made in 2024, and to ensure South Africa can generate the population-based cancer data needed to drive effective, equitable cancer prevention and control.

## **ACKNOWLEDGEMENTS**

The NCR would also like to thank the National Institute for Communicable Diseases for the continuous support for EPBCR. The NCR would like to thank the National Department of Health for additional funding that has assisted in the continued operations of the EPBCR.

The National Cancer Registry (NCR) would also like to thank all individuals, organisations and relevant stakeholders that played a critical role in the operations of the Ekurhuleni Population-Based Cancer Registry.

African Cancer Registry Network (AFCRN)

Ampath Laboratories

Arebaoke Hospice

Benoni Oncology Centre

Charlotte Maxeke Academic Hospital

Chris Hani Baragwanath Academic Hospital

Drs Gritzman & Thatcher Inc Laboratories

Eastrand Benoni Hospice

Edenvale Regional Hospital

Far East Regional Hospital

Gauteng Oncology Alberton Private Hospital

Gauteng Oncology Linmed Private Hospital

Gauteng Oncology Prostate-Clinic

Icon Oncology

International Agency for Research on Cancer (IARC)

International Association of Cancer Registries (IACR)

Lancet Laboratories

National Department of Health South Africa

National Health Laboratory Services

National Institute for Communicable Diseases

Pathcare Laboratories

Pholosong Regional Hospital

South African Medical Research Council (SAMRC)

South African Oncology Consortium (SAOC)

South African Paediatric Oncology Network

St Francis Hospice

Stepping Stone Hospice

Steve Biko Academic Hospital

Tambo Memorial Regional Hospital

Tembisa Regional Hospital

Thelle Mogoerane Regional Hospital

Union for International Cancer Control (UICC)

Vermaak Laboratories

World Health Organization (WHO)

## REFERENCES

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* 2006 Nov;3(11):1–23.
2. Ershler WB. Cancer: a disease of the elderly. *J Support Oncol.* 2003;1(4 Suppl 2):5–10.
3. Özdemir BC, Dotto GP. Racial differences in cancer susceptibility and survival: More than the color of the skin? *Trends in cancer.* 2017 Mar 1;3(3):181.
4. Chen WC, Singh E, Sengayi M, Bradshaw D, Mathew CG, Babb de Villiers C, et al. Johannesburg Cancer Study (JCS): contribution to knowledge and opportunities arising from 20 years of data collection in an African setting. *Cancer Epidemiol.* 2019;65:1–8.
5. Singh E, Naidu G, Davies M-A, Bohlius J. HIV-associated malignancies in children. *Curr Opin HIV AIDS.* 2017 Jan;12(1):77–83.
6. Rohner E, Sengayi M, Goeieman B, Michelow P, Firnhaber C, Maskew M, et al. Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg, South Africa. *Int J cancer.* 2017 Aug;141(3):488–96.
7. Lubuzo B, Ginindza T, Hlongwana K. Exploring barriers to lung cancer patient access, diagnosis, referral and treatment in Kwazulu-Natal, South Africa: the health providers' perspectives. *Transl Lung Cancer Res.* 2019;8(4):380.
8. Singh E, Underwood JM, Nattey C, Babb C, Sengayi M, Kellett P. South African National Cancer Registry: Effect of withheld data from private health systems on cancer incidence estimates. *S Afr Med J.* 2015 Jan;105(2):107–9.
9. Singh E, Ruff P, Babb C, Sengayi M, Beery M, Khoali L, et al. Establishment of a cancer surveillance programme: The South African experience. Vol. 16, *The Lancet Oncology.* 2015. p. e414–21.
10. IARC. The role and status of population-based cancer registration. 2007;X.
11. Department of Health. Regulations relating to cancer registration. *National Health Act,* 2003. 2011;(34248):2–8.

12. Boulle A, Heekes A, Tiffin N, Smith M, Mutemaringa T, Zinyakatira N, et al. Data Centre Profile: The Provincial Health Data Centre of the Western Cape Province, South Africa. *Int J Popul data Sci.* 2019 Nov 20;4(2).
13. Collinson MA, Mudzana T, Mutevedzi T, Kahn K, Maimela E, Gó Mez-Olivé FX, et al. Cohort Profile: South African Population Research Infrastructure Network (SAPRIN) Cohort Profile. *Int Epidemiol Assoc Int J Epidemiol.* 2022:206–16.
14. Global Initiative for Cancer Registries (GICR) | UICC [Internet]. [cited 2024 Jul 12]. Available from: <https://www.uicc.org/what-we-do/sharing-knowledge/global-initiative-cancer-registries-gicr>
15. KwaZulu-Natal Department of Health. Referral system: levels of care. 2014. p. 2017.
16. NHLS. 2017/18 NHLS Annual Report. Sandringham; 2018.
17. Parliament of the Republic of south Africa. Protection of Personal Information Act, 2013 Ensuring protection of your personal information and effective access to information. 2013;(4):154.
18. Chikandiwa A, Pisa PT, Sengayi M, Singh E, Delany-Moretlwe S. Patterns and trends of HPV-related cancers other than cervix in South Africa from 1994-2013. *Cancer Epidemiol.* 2019 Feb;58:121–9.
19. Singini MG, Sitas F, Bradshaw D, Chen WC, Motlhale M, Kamiza AB, et al. Ranking lifestyle risk factors for cervical cancer among Black women: A case-control study from Johannesburg, South Africa. *PLoS One.* 2021;16(12):e0260319.
20. Singini MG, Singh E, Bradshaw D, Chen WC, Motlhale M, Kamiza AB, et al. HPV types 16/18 L1 E6 and E7 proteins seropositivity and cervical cancer risk in HIV-positive and HIV-negative black South African women. *Infect Agent Cancer.* 2022 Mar;17(1):14.
21. International Agency for Research on Cancer. World Cancer report - Cancer research for cancer prevention. [Internet]. World Health Organization. 2020. p. 1–596. Available from: [https://www.iarc.who.int/cards\\_page/world-cancer-report/](https://www.iarc.who.int/cards_page/world-cancer-report/)
22. Ngwa W, Addai BW, Adewole I, Ainsworth V, Alaro J, Alatise OI, et al. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. *Lancet Oncol.* 2022 Jun 1;23(6):e251–312.

# **APPENDICES**

## Appendix 1: List of Data Sources

### **PUBLIC HOSPITALS**

- ❖ Charlotte Maxeke Johannesburg Academic Hospital
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Tshwane District Hospital
- ❖ Pholosong Regional Hospital
- ❖ Far East Rand Regional Hospital
- ❖ Thelle Mogoerane Regional Hospital
- ❖ Tembisa Regional Hospital
- ❖ Tambo Memorial Regional Hospital
- ❖ Edenvale Hospital

### **PRIVATE HEALTH FACILITIES**

- ❖ Benoni Oncology Centre
- ❖ Gauteng Prostate Oncology - Morehill Clinic
- ❖ Gauteng Oncology - Benoni Oncology Centre
- ❖ Gauteng Oncology - Linmed Hospital
- ❖ Netcare Clinton Oncology
- ❖ Independent Practitioners

### **HOSPICES**

- ❖ East Rand Hospice
- ❖ Flora Madiba Hospice
- ❖ Stepping Stone Hospice
- ❖ St Francis Hospice

### **SOUTH AFRICAN ONCOLOGY CONSORTIUM**

- ❖ Private Oncologists

### **ICON ONCOLOGY**

- ❖ Private Oncologists


### **PAEDIATRIC ONCOLOGY**

- ❖ CHOC Childhood cancer foundation
- ❖ Chris Hani Baragwanath Academic Hospital
- ❖ Steve Biko Academic Hospital
- ❖ Donald Gordon Medical Oncology Unit

### **NHLS**

- ❖ CDW pathology-based cancer reports

## Appendix 2: South African Cancer Notification Form

	<p><b>health</b></p> <p>Department Health REPUBLIC OF SOUTH AFRICA</p> <p>National Health Act, 2003 (Act No. 61 of 2003) Regulation Number 380</p>	<p>Republic of South Africa Department of Health</p> <p><b>CANCER REGISTRATION FORM</b></p>	<p>To be completed in duplicate in <b>BLOCK LETTERS</b>. Please mark with <input checked="" type="checkbox"/> the CORRECT box, where required. Original to be submitted to the National Cancer Register and copy to be retained: To be submitted to the National Cancer Register via: e-mail: cancer.registry@nhls.ac.za fax: 011 489 9132 / 011 489 9152 Post: P.O. Box 1038, Johannesburg, 2000.</p>
<b>A. PARTICULARS OF INDIVIDUAL</b>			
1. Name of facility <input type="text"/>			
USE PATIENT STICKER <i>if available</i>			
2. Surname <input type="text"/>			
3. Full names <input type="text"/>			
4. Date of birth <input type="text"/>			
5. Folder number <input type="text"/>			
6. Sex <input type="checkbox"/> Male <input type="checkbox"/> Female			
7. ID number/Passport number <input type="text"/>			
8. Race group <input type="checkbox"/> African <input type="checkbox"/> Coloured <input type="checkbox"/> White <input type="checkbox"/> Indian <input type="checkbox"/> Other _____			
9. Area of residence			
9.1 City/town/village <input type="text"/>			
9.2 Postal code <input type="text"/> 9.3 How long at this address? <input type="text"/> years			
Please record place of birth if not the same as current address			
9.4 City/town/village <input type="text"/>			
9.5 Postal code <input type="text"/>			
<b>B. RISK FACTOR PROFILE</b>			
10. Usual occupation of patient <input type="text"/> (If retired, give type of work done for most of working life)			
11. Type of industry/business <input type="text"/> (e.g Mining, farming etc)			
12. Did the patient ever smoke tobacco? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
13. Did the patient ever consume alcohol regularly? (that is, more than once a week) <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Unknown			
14. HIV status <input type="checkbox"/> Negative <input type="checkbox"/> Positive <input type="checkbox"/> Unknown			
<b>C. CLINICAL AND LABORATORY DETAILS</b>			
15. Date of diagnosis <input type="text"/>			
16. Cancer diagnosis and Histology <input type="text"/> 17. ICD-10 <input type="text"/> • <input type="text"/>			
<i>Please give all information available on the site, laterality, histology and behaviour of the tumour</i>			
18. Grade <input type="checkbox"/> Well differentiated <input type="checkbox"/> Moderately differentiated <input type="checkbox"/> Poorly differentiated <input type="checkbox"/> Unknown/Not applicable			
19. Stage <input type="checkbox"/> Primary/localised <input type="checkbox"/> Metastatic <input type="checkbox"/> Unknown/Not applicable			
20. Invasiveness <input type="checkbox"/> In-situ <input type="checkbox"/> Invasive			
21. Basis of diagnosis <input type="checkbox"/> Clinical <input type="checkbox"/> Clinical with investigation <input type="checkbox"/> Cytology/histopathology <input type="checkbox"/> Molecular <input type="checkbox"/> Death Certificate			
22. Prescribed treatment <input type="checkbox"/> Surgery <input type="checkbox"/> Radiation <input type="checkbox"/> Chemotherapy <input type="checkbox"/> Other <input type="checkbox"/> Palliation <input type="checkbox"/> Alternative <input type="checkbox"/> None			
<p><b>INFORMANT PARTICULARS</b></p> <p>Name (Print) _____</p> <p>MP/NC Number <input type="text"/></p> <p>Signature _____ Date _____</p>			<p><b>OFFICE CODING</b></p> <p><input type="text"/> • <input type="text"/></p> <p>M - <input type="text"/> / <input type="text"/> / <input type="text"/></p>

Appendix 3: Tables of Incidence by site, sex, age group and population, 2024

**Tables of ASR and Crude Incidence by population group**

Asian Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Breast	27	52,94	26	53,73	36,82	23,90	55,41
Colorectal	3	5,88	3	6,20	4,47	0,91	15,08
Ovary	3	5,88	3	6,20	4,46	0,92	15,05
Cervix	3	5,88	3	6,20	4,05	0,82	14,29
Primary site unknown	2	3,92	2	4,13	3,59	0,37	14,56
Stomach	2	3,92	2	4,13	2,99	0,36	13,00
Lung	2	3,92	2	4,13	2,46	0,28	12,00
Vulva	1	1,96	1	2,07	1,58	0,04	11,06
Pancreas	1	1,96	1	2,07	1,52	0,04	10,93
SCC of skin	1	1,96	1	2,07	1,52	0,04	10,92
Tongue	1	1,96	1	2,07	1,36	0,03	10,57
Non Hodgkin lymphoma	1	1,96	1	2,07	1,31	0,03	10,48
Uterus	1	1,96	1	2,07	1,31	0,03	10,48
Mesothelioma	1	1,96	1	2,07	1,31	0,03	10,48
Anus	1	1,96	1	2,07	1,24	0,03	10,32
Bladder	1	1,96	1	2,07	1,24	0,03	10,32
<b>All sites</b>	<b>51</b>	<b>100</b>	<b>50</b>	<b>103,35</b>	<b>71,23</b>	<b>27,86</b>	<b>234,95</b>

<b>Black Females: Crude and Age-Adjusted Incidence Rates/100 000</b>							
<b>Site</b>	<b>N (Obs)</b>	<b>N (Obs) Percent</b>	<b>N(Adj)</b>	<b>Crude Incidence</b>	<b>ASR</b>	<b>ASR 95% LCL</b>	<b>ASR 95% UCL</b>
Cervix	731	36,17	720	45,63	44,73	41,43	48,23
Breast	467	23,11	457	28,96	28,89	26,22	31,76
Uterus	116	5,74	116	7,35	8,54	7,03	10,27
Primary site unknown	96	4,75	93	5,89	6,26	5,03	7,70
Vulva	103	5,10	98	6,21	5,70	4,59	7,01
Colorectal	80	3,96	78	4,94	5,14	4,03	6,46
Non Hodgkin lymphoma	54	2,67	54	3,42	3,23	2,40	4,26
Anus	33	1,63	33	2,09	2,06	1,41	2,92
Oesophagus	25	1,24	25	1,58	1,97	1,24	2,94
Other specified	21	1,04	20	1,27	1,39	0,83	2,18
Leukaemia	22	1,09	21	1,33	1,27	0,77	1,98
Ovary	20	0,99	19	1,20	1,12	0,66	1,79
SCC of skin	21	1,04	20	1,27	1,09	0,65	1,74
Kaposi Sarcoma	20	0,99	18	1,14	0,94	0,54	1,53
Myeloma	11	0,54	11	0,70	0,82	0,41	1,46
Vagina	11	0,54	11	0,70	0,81	0,38	1,50
Hodgkin lymphoma	13	0,64	13	0,82	0,80	0,42	1,40
Stomach	11	0,54	11	0,70	0,79	0,39	1,42
Connective tissue	12	0,59	12	0,76	0,78	0,40	1,39
Melanoma	10	0,49	10	0,63	0,77	0,35	1,46
Ill defined	12	0,59	12	0,76	0,77	0,39	1,37
Thyroid	12	0,59	12	0,76	0,76	0,39	1,36
Brain, CNS	10	0,49	10	0,63	0,74	0,35	1,36
Lung	11	0,54	11	0,70	0,73	0,36	1,32
Pancreas	9	0,45	9	0,57	0,70	0,31	1,33
BCC	9	0,45	9	0,57	0,57	0,25	1,11
Naso-Oropharynx	9	0,45	9	0,57	0,56	0,25	1,08
Bladder	9	0,45	9	0,57	0,55	0,25	1,08
Liver & Bile duct	7	0,35	7	0,44	0,53	0,21	1,09
Larynx	5	0,25	5	0,32	0,36	0,12	0,85
Mouth	4	0,20	4	0,25	0,35	0,09	0,88
Endocrine	5	0,25	5	0,32	0,32	0,10	0,77
Eye	5	0,25	5	0,32	0,32	0,10	0,76
Bone	5	0,25	5	0,32	0,30	0,09	0,73
Tongue	5	0,25	4	0,25	0,30	0,08	0,75
Skin other	4	0,20	4	0,25	0,29	0,08	0,75
Kidney	5	0,25	4	0,25	0,28	0,08	0,72
Salivary gland	4	0,20	4	0,25	0,26	0,07	0,68
Haematology other	3	0,15	3	0,19	0,23	0,05	0,66
Small intestine	3	0,15	3	0,19	0,21	0,04	0,62
Mesothelioma	3	0,15	3	0,19	0,21	0,04	0,61
Placenta	4	0,20	4	0,25	0,19	0,05	0,55
Lip	1	0,05	1	0,06	0,04	0,00	0,32
<b>All sites</b>	<b>2021</b>	<b>100</b>	<b>1982</b>	<b>125,57</b>	<b>126,67</b>	<b>102,93</b>	<b>160,15</b>

Coloured Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	27	38,03	27	16,54	13,96	9,18	20,48
Cervix	18	25,35	17	10,42	8,07	4,68	13,17
SCC of skin	2	2,82	2	1,23	1,32	0,15	4,71
Thyroid	2	2,82	2	1,23	1,13	0,14	4,22
Oesophagus	2	2,82	2	1,23	1,12	0,14	4,21
Colorectal	2	2,82	2	1,23	0,96	0,11	3,83
Other specified	2	2,82	2	1,23	0,95	0,11	3,81
Ill defined	2	2,82	2	1,23	0,95	0,11	3,81
Brain, CNS	1	1,41	1	0,61	0,87	0,02	4,20
Uterus	2	2,82	2	1,23	0,86	0,10	3,61
Primary site unknown	1	1,41	1	0,61	0,60	0,02	3,40
Non Hodgkin lymphoma	1	1,41	1	0,61	0,53	0,01	3,21
Melanoma	1	1,41	1	0,61	0,53	0,01	3,21
Connective tissue	1	1,41	1	0,61	0,53	0,01	3,21
Leukaemia	1	1,41	1	0,61	0,53	0,01	3,21
Lung	1	1,41	1	0,61	0,52	0,01	3,20
Vulva	1	1,41	1	0,61	0,52	0,01	3,19
Liver & Bile duct	1	1,41	1	0,61	0,47	0,01	3,07
BCC	1	1,41	1	0,61	0,43	0,01	2,97
Ovary	1	1,41	1	0,61	0,43	0,01	2,97
Kaposi Sarcoma	1	1,41	1	0,61	0,43	0,01	2,96
<b>All sites</b>	<b>71</b>	<b>100</b>	<b>70</b>	<b>42,89</b>	<b>35,71</b>	<b>14,86</b>	<b>100,65</b>

White Females: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	CRUDE	ASR	ASR 95% LCL	ASR 95% UCL
Breast	261	37,02	261	191,78	101,38	88,75	115,80
Colorectal	67	9,50	67	49,23	25,65	19,39	33,88
Cervix	47	6,67	45	33,07	20,83	14,91	28,83
Ovary	25	3,55	25	18,37	10,65	6,55	16,98
Melanoma	27	3,83	26	19,10	10,07	6,39	15,86
Primary site unknown	29	4,11	26	19,10	9,06	5,73	14,49
Lung	29	4,11	29	21,31	8,93	5,87	14,03
Uterus	19	2,70	19	13,96	8,42	4,67	14,55
BCC	20	2,84	20	14,70	7,00	4,04	12,17
Thyroid	10	1,42	10	7,35	5,99	2,76	11,78
Skin other	12	1,70	12	8,82	4,49	1,98	9,48
Non Hodgkin lymphoma	15	2,13	14	10,29	4,28	2,22	8,63
SCC of skin	15	2,13	15	11,02	4,08	2,14	8,30
Liver & Bile duct	13	1,84	13	9,55	3,98	2,03	8,22
Stomach	10	1,42	10	7,35	3,94	1,80	8,48
Brain, CNS	7	0,99	7	5,14	3,32	1,29	7,88
Haematology other	10	1,42	10	7,35	3,13	1,41	7,26
Leukaemia	12	1,70	12	8,82	2,93	1,47	6,75
Bladder	10	1,42	10	7,35	2,78	1,28	6,71
Myeloma	8	1,13	7	5,14	2,50	0,94	6,60
Mesothelioma	8	1,13	8	5,88	2,42	1,01	6,32
Oesophagus	5	0,71	5	3,67	2,34	0,74	6,59
Pancreas	7	0,99	7	5,14	2,20	0,86	6,07
Vulva	5	0,71	5	3,67	1,76	0,51	5,70
Other specified	5	0,71	5	3,67	1,60	0,49	5,39
Connective tissue	4	0,57	4	2,94	1,55	0,34	5,56
Hodgkin lymphoma	2	0,28	2	1,47	1,33	0,09	5,86
Larynx	3	0,43	3	2,20	1,23	0,25	5,04
Kidney	3	0,43	3	2,20	1,09	0,22	4,83
Small intestine	3	0,43	3	2,20	1,09	0,22	4,83
Vagina	3	0,43	3	2,20	1,02	0,18	4,75
Anus	2	0,28	2	1,47	0,84	0,08	4,63
Salivary gland	2	0,28	2	1,47	0,60	0,06	4,24
Ill defined	1	0,14	1	0,73	0,39	0,01	4,03
Eye	2	0,28	1	0,73	0,35	0,01	3,96
Bone	1	0,14	1	0,73	0,35	0,01	3,96
Mouth	1	0,14	1	0,73	0,35	0,01	3,96
Endocrine	1	0,14	1	0,73	0,20	0,00	3,74
<b>All sites</b>	<b>704</b>	<b>100</b>	<b>695</b>	<b>510,63</b>	<b>264,12</b>	<b>180,71</b>	<b>446,14</b>

Asian Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	17	39,53	17	28,87	21,05	12,21	35,23
Brain, CNS	2	4,65	2	3,40	6,09	0,47	21,48
Colorectal	4	9,30	4	6,79	4,60	1,23	14,24
Kidney	2	4,65	2	3,40	4,23	0,43	15,79
Primary site unknown	2	4,65	2	3,40	3,98	0,36	15,36
Bladder	4	9,30	3	5,09	3,60	0,73	12,98
Mouth	1	2,33	1	1,70	2,84	0,07	14,06
Liver & Bile duct	2	4,65	2	3,40	2,05	0,25	10,70
Hodgkin lymphoma	1	2,33	1	1,70	1,69	0,04	10,86
Myeloma	1	2,33	1	1,70	1,41	0,04	10,22
Tongue	1	2,33	1	1,70	1,41	0,04	10,22
Lung	1	2,33	1	1,70	1,39	0,04	10,15
BCC	1	2,33	1	1,70	1,37	0,03	10,12
Oesophagus	1	2,33	1	1,70	1,21	0,03	9,77
Larynx	1	2,33	1	1,70	1,09	0,03	9,53
Testis	1	2,33	1	1,70	0,93	0,02	9,23
<b>All sites</b>	<b>42</b>	<b>98</b>	<b>41</b>	<b>69,65</b>	<b>58,94</b>	<b>16,02</b>	<b>219,94</b>

<b>Black Males: Crude and Age Adjusted Incidence Rates/100 000</b>							
<b>Site</b>	<b>N (Obs)</b>	<b>N (Obs) Percent</b>	<b>N(Adj)</b>	<b>Crude Incidence</b>	<b>ASR</b>	<b>ASR 95% LCL</b>	<b>ASR 95% UCL</b>
Prostate	597	48,62	585	34,84	55,24	50,33	60,45
Colorectal	61	4,97	60	3,57	4,63	3,39	6,15
Lung	45	3,66	45	2,68	3,52	2,48	4,83
Primary site unknown	44	3,58	42	2,50	3,08	2,19	4,21
Non Hodgkin lymphoma	45	3,66	44	2,62	2,51	1,80	3,45
Leukaemia	33	2,69	31	1,85	2,49	1,54	3,76
Oesophagus	33	2,69	32	1,91	2,41	1,63	3,45
Stomach	26	2,12	26	1,55	2,38	1,37	3,75
Penis	34	2,77	33	1,97	2,34	1,58	3,33
Kaposi Sarcoma	33	2,69	32	1,91	1,87	1,25	2,71
SCC of skin	28	2,28	26	1,55	1,78	1,14	2,67
Bladder	21	1,71	21	1,25	1,61	0,98	2,49
Larynx	17	1,38	17	1,01	1,29	0,73	2,10
Anus	18	1,47	17	1,01	1,24	0,61	2,18
Skin other	19	1,55	19	1,13	1,21	0,70	1,97
Naso-Oropharynx	15	1,22	15	0,89	1,05	0,57	1,78
Hodgkin lymphoma	17	1,38	15	0,89	0,83	0,45	1,46
Other specified	12	0,98	12	0,71	0,77	0,39	1,41
Breast	11	0,90	11	0,66	0,77	0,37	1,43
Ill defined	11	0,90	11	0,66	0,72	0,34	1,37
Liver & Bile duct	12	0,98	12	0,71	0,72	0,35	1,33
Myeloma	11	0,90	11	0,66	0,64	0,31	1,22
BCC	10	0,81	8	0,48	0,62	0,26	1,26
Connective tissue	11	0,90	11	0,66	0,54	0,26	1,05
Melanoma	5	0,41	5	0,30	0,49	0,09	1,33
Pancreas	7	0,57	7	0,42	0,46	0,18	1,01
Kidney	7	0,57	7	0,42	0,44	0,17	0,96
Eye	3	0,24	3	0,18	0,44	0,06	1,29
Brain, CNS	7	0,57	7	0,42	0,43	0,16	0,95
Tongue	5	0,41	5	0,30	0,40	0,13	0,96
Mouth	4	0,33	4	0,24	0,36	0,10	0,92
Endocrine	4	0,33	4	0,24	0,31	0,08	0,83
Salivary gland	4	0,33	4	0,24	0,29	0,08	0,78
Testis	5	0,41	5	0,30	0,28	0,09	0,74
Thyroid	3	0,24	3	0,18	0,24	0,05	0,74
Mesothelioma	2	0,16	2	0,12	0,17	0,02	0,62
Small intestine	2	0,16	2	0,12	0,14	0,02	0,57
Haematology other	2	0,16	2	0,12	0,13	0,02	0,53
Lip	2	0,16	2	0,12	0,13	0,02	0,53
Burkitt lymphoma	1	0,08	1	0,06	0,05	0,00	0,42
Bone	1	0,08	1	0,06	0,03	0,00	0,38
<b>All sites</b>	<b>1228</b>	<b>100</b>	<b>1200</b>	<b>71,51</b>	<b>99,05</b>	<b>76,29</b>	<b>133,37</b>

Coloured Males: Crude and Age Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	10	25,64	10	5,65	5,30	2,52	9,99
BCC	5	12,82	4	2,26	3,25	0,72	8,50
Primary site unknown	3	7,69	3	1,70	2,52	0,36	7,56
Lung	4	10,26	4	2,26	2,14	0,57	5,77
Colorectal	4	10,26	4	2,26	1,92	0,51	5,34
SCC of skin	1	2,56	1	0,57	1,52	0,04	6,41
Melanoma	2	5,13	2	1,13	0,97	0,12	3,97
Larynx	1	2,56	1	0,57	0,59	0,01	3,50
Non Hodgkin lymphoma	1	2,56	1	0,57	0,59	0,01	3,50
Bladder	1	2,56	1	0,57	0,54	0,01	3,37
Mouth	1	2,56	1	0,57	0,48	0,01	3,23
Thyroid	1	2,56	1	0,57	0,48	0,01	3,23
Oesophagus	1	2,56	1	0,57	0,48	0,01	3,23
Naso-Oropharynx	1	2,56	1	0,57	0,48	0,01	3,23
Liver & Bile duct	1	2,56	1	0,57	0,48	0,01	3,23
Tongue	1	2,56	1	0,57	0,43	0,01	3,12
Haematology other	1	2,56	1	0,57	0,43	0,01	3,12
<b>All sites</b>	<b>39</b>	<b>100</b>	<b>38</b>	<b>21,53</b>	<b>22,60</b>	<b>4,94</b>	<b>80,30</b>

White Males: Crude and Age-Adjusted Incidence Rates/100 000							
Site	N (Obs)	N (Obs) Percent	N(Adj)	Crude Incidence	ASR	ASR 95% LCL	ASR 95% UCL
Prostate	260	34,39	254	166,59	67,39	59,09	77,18
Colorectal	87	11,51	87	57,06	26,28	20,77	33,47
Melanoma	46	6,08	46	30,17	14,01	10,06	19,76
Primary site unknown	35	4,63	35	22,96	11,54	7,83	17,14
Non Hodgkin lymphoma	18	2,38	17	11,15	8,11	3,96	14,83
Lung	28	3,70	28	18,36	7,93	5,18	12,58
Testis	12	1,59	12	7,87	7,09	3,54	13,04
BCC	28	3,70	28	18,36	7,06	4,60	11,43
Stomach	19	2,51	19	12,46	5,97	3,49	10,48
SCC of skin	22	2,91	22	14,43	5,29	3,25	9,31
Skin other	17	2,25	17	11,15	5,09	2,83	9,44
Brain, CNS	10	1,32	10	6,56	4,72	1,92	10,02
Bladder	17	2,25	15	9,84	4,70	2,60	8,88
Pancreas	16	2,12	16	10,49	4,48	2,46	8,60
Oesophagus	12	1,59	12	7,87	3,93	1,95	8,10
Liver & Bile duct	12	1,59	12	7,87	3,56	1,77	7,54
Kidney	11	1,46	10	6,56	2,89	1,34	6,68
Leukaemia	12	1,59	11	7,21	2,87	1,38	6,60
Hodgkin lymphoma	5	0,66	5	3,28	2,82	0,69	7,79
Ill defined	6	0,79	6	3,94	2,65	0,63	7,47
Myeloma	9	1,19	9	5,90	2,60	1,11	6,40
Tongue	7	0,93	7	4,59	2,41	0,94	6,23
Naso-Oropharynx	8	1,06	8	5,25	2,21	0,93	5,83
Other specified	8	1,06	8	5,25	2,13	0,87	5,75
Breast	6	0,79	6	3,94	1,91	0,69	5,54
Larynx	5	0,66	5	3,28	1,77	0,57	5,44
Salivary gland	6	0,79	6	3,94	1,77	0,57	5,44
Connective tissue	5	0,66	5	3,28	1,69	0,50	5,39
Endocrine	1	0,13	1	0,66	1,66	0,04	7,34
Thyroid	6	0,79	6	3,94	1,64	0,58	5,17
Haematology other	6	0,79	6	3,94	1,60	0,51	5,17
Penis	4	0,53	4	2,62	1,54	0,40	5,25
Mesothelioma	5	0,66	5	3,28	1,15	0,36	4,52
Mouth	3	0,40	3	1,97	0,92	0,18	4,37
Bone	1	0,13	1	0,66	0,36	0,01	3,78
Lip	1	0,13	1	0,66	0,33	0,01	3,72
Anus	1	0,13	1	0,66	0,30	0,01	3,67
Kaposi Sarcoma	1	0,13	1	0,66	0,23	0,01	3,59
<b>All sites</b>	<b>756</b>	<b>100</b>	<b>745</b>	<b>488,66</b>	<b>224,60</b>	<b>147,63</b>	<b>392,94</b>

## Age-Specific Incidence Rates /100 000 and Lifetime Risk reported as 1: x

ALL FEMALES																		
Site	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	3,52	2,52	3,79	5,16	11,28	33,26	61,39	121,98	188,76	262,20	289,22	389,32	432,03	550,39	688,39	639,80	1267,17	7
All sites but C44	3,52	2,52	3,79	5,16	10,62	32,69	60,41	117,73	184,10	256,99	282,88	380,94	427,61	530,52	673,74	619,16	1024,76	7
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,97	1,42	4,08	3,72	4,53	2,40	2,95	3,97	5,86	30,96	0,00	669
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,49	0,95	1,17	2,23	4,53	2,40	1,47	5,96	8,79	10,32	66,11	715
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,49	0,47	1,75	0,74	0,00	1,20	2,95	7,95	8,79	5,16	33,06	822
Bone	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,47	0,00	0,74	0,00	1,20	0,00	1,99	0,00	5,16	0,00	4033
Brain, CNS	0,59	1,89	0,00	0,00	0,00	0,00	0,49	0,00	0,00	2,23	2,72	2,40	4,42	3,97	0,00	0,00	0,00	1069
Breast	0,00	0,00	0,00	0,00	1,99	9,58	15,10	33,57	46,02	80,45	91,57	99,43	134,18	127,17	219,70	185,75	253,43	24
Cervix	0,00	0,00	0,00	0,00	0,66	5,07	18,03	48,23	77,48	96,84	93,39	130,57	89,95	103,32	114,24	87,71	66,11	26
Colorectal	0,00	0,00	0,00	0,65	0,66	2,82	3,90	4,26	4,08	8,19	11,79	15,57	42,76	47,69	46,87	30,96	99,17	106
Connective tissue	0,00	0,63	0,63	0,00	0,00	1,13	0,00	1,42	0,00	2,23	0,91	0,00	1,47	5,96	0,00	0,00	22,04	1391
Endocrine	0,00	0,00	0,63	0,00	0,66	0,00	0,00	0,00	0,58	0,00	0,00	2,40	0,00	0,00	0,00	0,00	11,02	4684
Eye	0,00	0,00	0,00	0,65	0,00	0,56	0,49	0,00	0,00	0,74	0,00	0,00	2,95	1,99	0,00	0,00	0,00	2711
Haematology other	0,59	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,49	0,00	1,20	2,95	1,99	8,79	5,16	22,04	1176
Hodgkin lymphoma	0,00	0,00	0,00	1,29	2,65	1,13	0,00	0,00	2,33	1,49	0,00	0,00	0,00	0,00	2,93	0,00	0,00	1693
Ill defined	0,00	0,00	0,00	0,00	0,00	0,56	0,00	1,42	0,00	1,49	1,81	2,40	1,47	3,97	5,86	0,00	0,00	1054
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,56	4,38	0,47	1,75	1,49	1,81	1,20	1,47	0,00	0,00	5,16	0,00	1524
Kidney	0,00	0,00	0,63	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,00	3,59	1,47	0,00	5,86	0,00	0,00	1628
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,74	3,63	0,00	1,47	3,97	0,00	0,00	0,00	2039
Leukaemia	0,59	0,00	1,26	1,29	0,00	0,00	1,46	0,95	2,91	0,74	0,00	1,20	2,95	9,93	11,72	10,32	55,09	572
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,47	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	42554
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	3,63	1,20	4,42	5,96	14,65	5,16	33,06	658
Lung	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,58	2,23	2,72	5,99	8,85	11,92	20,51	30,96	55,09	375
Melanoma	1,17	0,00	0,00	0,00	0,00	0,00	0,49	2,36	0,58	1,49	2,72	4,79	4,42	11,92	8,79	25,80	33,06	517

Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,20	0,00	9,93	5,86	20,64	0,00	1178
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,74	0,91	0,00	0,00	1,99	2,93	0,00	11,02	3045	
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,49	0,91	3,59	7,37	7,95	5,86	5,16	11,02	737	
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,91	0,00	0,00	0,00	4,42	1,99	0,00	0,00	0,00	2146	
Non Hodgkin lymphoma	0,00	0,00	0,00	0,65	1,33	3,38	3,90	2,36	4,08	5,96	5,44	5,99	8,85	13,91	8,79	5,16	66,11	310	
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,95	1,17	2,98	1,81	4,79	7,37	7,95	11,72	5,16	44,08	517	
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,49	1,89	0,58	2,23	2,72	2,40	4,42	11,92	5,86	10,32	11,02	616	
Ovary	0,00	0,00	0,00	0,00	0,66	0,00	2,44	0,95	2,33	4,47	4,53	3,59	11,80	17,88	2,93	15,48	22,04	388	
Pancreas	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,58	0,74	0,00	1,20	1,47	13,91	8,79	5,16	11,02	734	
Placenta	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,47	1,17	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9091	
Primary site unknown	0,59	0,00	0,63	0,65	0,66	1,69	0,97	4,26	6,41	9,68	14,51	23,96	19,17	27,82	29,29	41,28	55,09	143	
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,49	2,84	3,50	2,23	1,81	3,59	2,95	7,95	0,00	10,32	110,19	789	
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,49	0,00	0,00	0,00	0,91	1,20	1,47	0,00	2,93	5,16	0,00	2858	
Skin other	0,00	0,00	0,00	0,00	0,66	0,56	0,00	0,47	0,00	0,74	0,00	2,40	0,00	5,96	5,86	0,00	55,09	1202	
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,91	3,59	1,47	0,00	2,93	0,00	0,00	2248	
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,49	0,00	0,58	1,49	3,63	2,40	7,37	5,96	8,79	0,00	22,04	652	
Thyroid	0,00	0,00	0,00	0,00	0,00	1,13	1,46	0,95	2,33	2,98	1,81	3,59	1,47	1,99	5,86	0,00	0,00	849	
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,91	2,40	1,47	1,99	5,86	0,00	0,00	1584	
Uterus	0,00	0,00	0,00	0,00	0,00	1,69	0,97	1,42	2,91	0,74	6,35	33,54	33,91	43,71	82,02	61,92	44,08	97	
Vagina	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,47	1,17	1,49	0,91	2,40	0,00	0,00	5,86	5,16	22,04	1556	
Vulva	0,00	0,00	0,00	0,00	1,33	0,56	3,41	8,51	15,15	14,15	15,41	8,39	4,42	7,95	2,93	10,32	33,06	244	

ASIAN FEMALES

Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	0,00	0,00	58,86	23,32	206,42	0,00	177,56	117,79	203,42	197,14	148,43	459,35	197,99	454,65	13
All sites but C44	0,00	0,00	0,00	0,00	0,00	58,86	23,32	206,42	0,00	177,56	117,79	203,42	197,14	148,43	459,35	197,99	303,10	13
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,64	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	969
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	20,64	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	969
Breast	0,00	0,00	0,00	0,00	0,00	29,43	23,32	103,21	0,00	152,19	0,00	169,51	39,43	148,43	196,87	98,99	0,00	24
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	0,00	41,28	0,00	0,00	0,00	0,00	39,43	0,00	0,00	0,00	0,00	248
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	78,86	0,00	65,62	0,00	0,00	139
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29,45	0,00	0,00	0,00	0,00	98,99	0,00	680
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	65,62	0,00	0,00	305
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	65,62	0,00	0,00	305
Ovary	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	58,89	0,00	0,00	0,00	0,00	0,00	151,55	340
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	25,37	0,00	0,00	0,00	0,00	0,00	0,00	0,00	789
Primary site unknown	0,00	0,00	0,00	0,00	0,00	29,43	0,00	20,64	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	400
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	151,55	
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29,45	0,00	0,00	0,00	0,00	0,00	151,55	680
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	33,90	0,00	0,00	0,00	0,00	0,00	590
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	65,62	0,00	0,00	305
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	39,43	0,00	0,00	0,00	0,00	508

**BLACK FEMALES**

Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	4,11	2,26	4,54	6,27	13,78	34,99	68,85	132,95	224,44	315,63	341,93	398,45	348,11	423,93	458,04	428,55	343,72	8
All sites but C44	4,11	2,26	4,54	6,27	12,92	34,99	68,20	127,91	219,67	312,26	337,55	395,02	346,12	405,83	454,22	428,55	330,50	8
Anus	0,00	0,00	0,00	0,00	0,00	0,00	1,30	1,26	4,78	5,62	7,31	3,43	3,98	5,17	3,82	38,96	0,00	546
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,26	0,80	1,12	2,92	0,00	0,00	5,17	3,82	0,00	0,00	1326
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,65	0,00	2,39	1,12	0,00	1,72	0,00	7,75	0,00	0,00	0,00	1468
Bone	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,63	0,00	1,12	0,00	1,72	0,00	0,00	0,00	6,49	0,00	4729
Brain, CNS	0,69	1,51	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,25	2,92	1,72	1,99	2,58	0,00	0,00	0,00	1465
Breast	0,00	0,00	0,00	0,00	2,58	9,89	16,24	33,40	51,73	79,75	90,60	82,44	91,50	59,45	99,24	110,38	66,10	33
Cervix	0,00	0,00	0,00	0,00	0,86	6,08	23,38	57,34	94,71	134,79	140,28	166,60	105,43	121,49	125,96	97,40	52,88	21
Colorectal	0,00	0,00	0,00	0,78	0,86	2,28	3,90	5,04	4,78	7,86	8,77	13,74	25,86	31,02	15,27	12,99	13,22	167
Connective tissue	0,00	0,75	0,76	0,00	0,00	1,52	0,00	1,26	0,00	2,25	1,46	0,00	1,99	5,17	0,00	0,00	0,00	1320
Endocrine	0,00	0,00	0,76	0,00	0,86	0,00	0,00	0,00	0,80	0,00	0,00	3,43	0,00	0,00	0,00	0,00	0,00	3419
Eye	0,00	0,00	0,00	0,78	0,00	0,76	0,65	0,00	0,00	1,12	0,00	0,00	1,99	0,00	0,00	0,00	0,00	3774
Haematology other	0,69	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,12	0,00	0,00	1,99	0,00	0,00	0,00	0,00	5264
Hodgkin lymphoma	0,00	0,00	0,00	1,57	3,45	0,76	0,00	0,00	3,18	2,25	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1785
Ill defined	0,00	0,00	0,00	0,00	0,00	0,76	0,00	1,89	0,00	2,25	1,46	0,00	1,99	5,17	7,63	0,00	0,00	946
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,76	5,20	0,00	2,39	2,25	1,46	1,72	1,99	0,00	0,00	6,49	0,00	1269
Kidney	0,00	0,00	0,76	0,00	0,00	0,00	0,00	0,00	0,00	1,12	0,00	1,72	0,00	0,00	3,82	0,00	0,00	2696
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,12	4,38	0,00	0,00	2,58	0,00	0,00	0,00	2476
Leukaemia	0,69	0,00	1,51	1,57	0,00	0,00	1,95	1,26	3,18	1,12	0,00	1,72	3,98	5,17	3,82	0,00	0,00	771
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,63	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	31747
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	1,72	3,98	5,17	3,82	0,00	0,00	1239
Lung	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,00	0,80	3,37	1,46	3,43	0,00	2,58	0,00	12,99	0,00	1613
Melanoma	1,37	0,00	0,00	0,00	0,00	0,00	0,00	1,26	0,00	1,12	1,46	0,00	0,00	0,00	0,00	12,99	26,44	3839
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,58	0,00	12,99	0,00	7752

Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,12	1,46	0,00	0,00	0,00	3,82	0,00	13,22	3126
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,12	1,46	5,15	5,97	2,58	7,63	0,00	0,00	837
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,98	0,00	0,00	0,00	5,97	2,58	0,00	0,00	0,00	1597
Non Hodgkin lymphoma	0,00	0,00	0,00	0,78	1,72	4,56	5,20	3,15	5,57	7,86	5,84	5,15	11,94	10,34	0,00	6,49	0,00	323
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,26	0,80	2,25	2,92	6,87	3,98	7,75	15,27	6,49	52,88	487
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,65	1,26	0,80	3,37	2,92	3,43	3,98	10,34	3,82	6,49	13,22	655
Ovary	0,00	0,00	0,00	0,00	0,00	0,00	1,95	1,26	3,18	3,37	2,92	0,00	0,00	12,92	0,00	0,00	0,00	782
Pancreas	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,00	0,80	0,00	0,00	1,72	0,00	10,34	3,82	0,00	13,22	1147
Placenta	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,63	1,59	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	6712
Primary site unknown	0,69	0,00	0,76	0,78	0,86	1,52	0,65	3,78	8,75	11,23	20,46	29,20	11,94	25,85	30,54	19,48	13,22	137
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,65	3,78	3,98	2,25	1,46	1,72	1,99	7,75	0,00	0,00	0,00	849
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,65	0,00	0,00	0,00	1,46	1,72	0,00	0,00	3,82	0,00	0,00	2615
Skin other	0,00	0,00	0,00	0,00	0,86	0,00	0,00	0,00	0,00	0,00	0,00	1,72	0,00	5,17	0,00	0,00	0,00	2581
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	3,43	0,00	0,00	0,00	0,00	0,00	4090
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,80	2,25	1,46	1,72	5,97	5,17	3,82	0,00	0,00	944
Thyroid	0,00	0,00	0,00	0,00	0,00	0,76	0,65	0,63	0,80	3,37	1,46	1,72	1,99	0,00	7,63	0,00	0,00	1053
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,46	1,72	0,00	2,58	3,82	0,00	0,00	2088
Uterus	0,00	0,00	0,00	0,00	0,00	0,76	0,65	1,89	3,18	1,12	8,77	34,35	43,76	51,70	95,42	64,93	39,66	83
Vagina	0,00	0,00	0,00	0,00	0,00	0,76	0,00	0,63	1,59	2,25	0,00	1,72	0,00	0,00	7,63	0,00	26,44	1372
Vulva	0,00	0,00	0,00	0,00	1,72	0,76	4,55	9,45	19,10	21,34	20,46	12,02	3,98	7,75	3,82	12,99	13,22	191

COLOURED FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	8,69	0,00	0,00	0,00	0,00	0,00	56,72	70,87	89,88	72,53	118,42	143,98	158,51	105,06	0,00	79,34	25
All sites but C44	0,00	8,69	0,00	0,00	0,00	0,00	0,00	56,72	70,87	89,88	72,53	107,65	130,89	158,51	105,06	0,00	0,00	25
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,77	0,00	0,00	0,00	0,00	0,00	1858
Brain, CNS	0,00	8,69	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2302
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,18	39,37	49,93	41,45	10,77	91,63	35,22	26,26	0,00	0,00	65
Cervix	0,00	0,00	0,00	0,00	0,00	0,00	0,00	28,36	23,62	9,99	10,36	43,06	0,00	35,22	52,53	0,00	0,00	99
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,77	0,00	17,61	0,00	0,00	0,00	705
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,61	0,00	0,00	0,00	1136
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,36	10,77	0,00	0,00	0,00	0,00	0,00	947
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,09	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2821
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26,26	0,00	0,00	762
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,87	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2542
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,09	0,00	0,00	0,00	0,00	1528
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,61	0,00	0,00	0,00	1136
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,61	0,00	0,00	0,00	1136

Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,99	0,00	0,00	13,09	0,00	0,00	0,00	0,00	867
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,09	0,00	0,00	0,00	0,00	13,09	0,00	0,00	0,00	0,00	992
Ovary	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,77	0,00	0,00	0,00	0,00	0,00	1858
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,99	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2003
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,09	0,00	0,00	0,00	79,34	1528
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,99	0,00	0,00	0,00	17,61	0,00	0,00	0,00	725
Uterus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	21,53	0,00	0,00	0,00	0,00	0,00	929
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,36	0,00	0,00	0,00	0,00	0,00	0,00	1931

WHITE FEMALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	0,00	14,75	132,38	140,13	215,46	236,31	477,03	646,10	671,44	1013,4 2	1154,5 3	1377,7 2	970,82	1660,5 5	4
All sites but C44	0,00	0,00	0,00	0,00	14,75	119,14	128,45	205,67	226,86	438,87	610,20	631,95	1002,7 5	1119,5 5	1323,1 6	900,22	1289,3 6	4
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,45	0,00	0,00	0,00	0,00	0,00	13,64	0,00	0,00	867
BCC	0,00	0,00	0,00	0,00	0,00	0,00	11,68	0,00	9,45	19,08	26,92	9,87	10,67	11,66	27,28	35,30	117,21	158
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	21,34	11,66	40,92	17,65	58,61	271
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,66	0,00	0,00	0,00	1716
Brain, CNS	0,00	0,00	0,00	0,00	0,00	0,00	11,68	0,00	0,00	9,54	8,97	9,87	21,34	11,66	0,00	0,00	0,00	274
Breast	0,00	0,00	0,00	0,00	0,00	26,48	35,03	107,73	66,17	228,98	314,08	276,48	373,37	419,83	600,20	317,72	351,64	9
Cervix	0,00	0,00	0,00	0,00	0,00	13,24	0,00	39,17	75,62	57,24	53,84	39,50	64,01	34,99	40,92	35,30	39,07	48
Colorectal	0,00	0,00	0,00	0,00	0,00	26,48	11,68	9,79	9,45	38,16	62,82	39,50	138,68	128,28	150,05	70,61	156,29	33
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,79	0,00	9,54	0,00	0,00	0,00	0,00	0,00	0,00	39,07	1035
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	19,54	
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,66	0,00	0,00	0,00	1716
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,54	0,00	9,87	10,67	11,66	40,92	17,65	39,07	242
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	13,24	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	13,64	0,00	0,00	745
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,87	0,00	0,00	0,00	0,00	0,00	2027
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,87	10,67	0,00	13,64	0,00	0,00	586
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,97	0,00	10,67	11,66	0,00	0,00	0,00	639
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34,99	27,28	35,30	97,68	322
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	26,92	0,00	10,67	11,66	54,56	17,65	58,61	193

Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,97	29,62	53,34	58,31	95,49	52,95	97,68	82
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	11,68	19,59	9,45	9,54	17,95	39,50	32,00	58,31	40,92	52,95	19,54	84
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,87	0,00	46,65	13,64	35,30	0,00	286
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,66	0,00	0,00	0,00	1716
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,54	0,00	0,00	21,34	23,32	0,00	17,65	19,54	370
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,54	17,95	9,87	0,00	23,32	27,28	0,00	117,21	228
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,45	9,54	0,00	0,00	21,34	11,66	0,00	0,00	0,00	385
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,97	0,00	0,00	23,32	13,64	17,65	0,00	436
Ovary	0,00	0,00	0,00	0,00	14,75	0,00	11,68	0,00	0,00	28,62	8,97	19,75	85,34	46,65	13,64	52,95	19,54	88
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,67	34,99	27,28	17,65	0,00	275
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,79	0,00	19,08	17,95	19,75	64,01	34,99	27,28	70,61	78,14	104
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,54	8,97	19,75	0,00	11,66	0,00	35,30	156,29	401
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	10,67	0,00	0,00	17,65	0,00	1875
Skin other	0,00	0,00	0,00	0,00	0,00	13,24	0,00	9,79	0,00	9,54	0,00	9,87	0,00	11,66	27,28	0,00	97,68	246
Small intestine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,87	10,67	0,00	13,64	0,00	0,00	586
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	11,68	0,00	0,00	0,00	17,95	9,87	21,34	11,66	27,28	0,00	19,54	201
Thyroid	0,00	0,00	0,00	0,00	0,00	13,24	23,35	9,79	28,36	0,00	8,97	19,75	0,00	0,00	0,00	0,00	0,00	194
Uterus	0,00	0,00	0,00	0,00	0,00	26,48	11,68	0,00	9,45	0,00	8,97	59,25	10,67	23,32	27,28	35,30	19,54	113
Vagina	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,97	9,87	0,00	0,00	0,00	17,65	0,00	1062
Vulva	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,45	0,00	8,97	0,00	0,00	11,66	0,00	0,00	39,07	665

ALL MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	2,41	5,24	5,86	6,70	7,29	14,16	21,03	32,47	57,23	118,98	185,69	312,69	482,66	564,05	741,11	759,06	944,99	8
All sites but C44	2,41	5,24	5,86	6,03	6,56	13,51	17,71	31,41	52,68	114,57	172,74	297,80	459,74	536,75	694,79	672,43	842,27	9
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,66	0,65	3,53	0,00	4,96	1,43	3,64	2,57	0,00	6,85	1029
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,55	0,53	0,00	0,00	4,32	3,72	7,16	14,56	15,44	37,13	47,93	433
Bladder	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,00	0,00	3,53	10,80	4,96	12,89	16,38	7,72	0,00	20,54	352
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,53	0,00	0,00	0,00	0,00	1,43	0,00	0,00	0,00	0,00	10205
Brain, CNS	0,60	0,00	0,65	0,00	0,73	1,29	0,55	0,53	1,30	0,00	2,16	2,48	0,00	5,46	2,57	4,13	6,85	1092
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,53	0,00	1,76	3,24	1,24	7,16	3,64	7,72	0,00	0,00	791
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	31251
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	2,77	3,19	4,55	12,34	14,04	24,82	31,51	54,59	46,32	53,63	54,78	104
Connective tissue	0,00	0,65	0,65	0,00	0,73	0,00	0,55	1,06	2,60	0,88	3,24	0,00	0,00	1,82	0,00	4,13	0,00	1643
Endocrine	0,00	0,65	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,48	2,86	0,00	0,00	0,00	0,00	3339
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,24	1,43	0,00	0,00	0,00	6,85	7491
Haematology other	0,00	0,00	0,65	0,00	0,00	0,00	0,00	0,00	0,00	0,88	2,16	1,24	0,00	0,00	2,57	8,25	6,85	2667
Hodgkin lymphoma	0,60	1,31	0,00	2,01	1,46	0,64	1,66	1,06	2,60	1,76	0,00	0,00	1,43	0,00	5,15	0,00	0,00	1017
Ill defined	0,00	0,00	0,65	0,00	0,00	0,00	0,55	1,60	0,00	0,00	0,00	3,72	5,73	5,46	2,57	4,13	0,00	987
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,73	0,64	1,66	2,66	1,30	5,29	3,24	9,93	1,43	0,00	7,72	4,13	0,00	579
Kidney	0,60	0,00	0,65	0,00	0,00	0,00	0,00	0,53	0,65	0,00	4,32	1,24	7,16	0,00	7,72	4,13	13,70	875
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,55	0,00	1,30	0,88	1,08	4,96	14,32	5,46	5,15	0,00	0,00	594
Leukaemia	0,00	1,31	1,95	2,01	0,00	0,00	0,55	2,13	1,30	4,41	2,16	1,24	7,16	9,10	12,87	20,63	20,54	433
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,88	0,00	2,48	0,00	0,00	0,00	0,00	0,00	5953
Liver & Bile duct	0,00	0,00	0,65	0,00	0,00	0,00	1,11	0,00	2,60	1,76	3,24	1,24	8,59	5,46	5,15	8,25	6,85	672
Lung	0,00	0,00	0,00	0,00	0,00	1,29	0,55	1,60	0,00	7,93	4,32	13,65	20,05	16,38	30,88	28,88	41,09	207
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,55	0,53	1,30	2,64	8,64	6,20	11,46	9,10	15,44	24,75	54,78	359
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,24	0,00	1,82	10,29	4,13	0,00	1499

Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,24	5,73	3,64	2,57	0,00	6,85	1518
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,55	1,06	0,65	2,64	3,24	1,24	4,30	5,46	2,57	8,25	6,85	922	
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,53	0,65	2,64	1,08	4,96	8,59	3,64	5,15	4,13	13,70	718	
Non Hodgkin lymphoma	0,00	0,65	0,00	0,00	0,00	2,57	1,11	1,60	9,11	11,46	7,56	6,20	5,73	7,28	10,29	12,38	0,00	315	
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,53	2,60	0,88	6,48	13,65	15,75	10,92	5,15	20,63	0,00	358	
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,30	2,64	2,16	6,20	4,30	1,82	0,00	16,50	0,00	1086	
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,30	0,88	2,16	7,44	2,86	5,46	5,15	16,50	6,85	793	
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,90	4,41	8,64	4,96	5,73	5,46	15,44	8,25	0,00	413	
Primary site unknown	0,60	0,00	0,00	0,67	0,00	0,00	0,55	3,19	2,60	8,81	4,32	14,89	18,62	9,10	41,17	12,38	54,78	192	
Prostate	0,00	0,00	0,00	0,67	2,19	1,93	2,21	2,13	7,15	26,44	62,62	138,97	221,99	322,05	424,59	379,53	472,49	17	
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,90	2,64	7,56	4,96	7,16	12,74	20,59	28,88	27,39	336	
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,65	0,00	2,16	1,24	2,86	1,82	0,00	8,25	6,85	2291	
Skin other	0,00	0,00	0,00	0,67	0,73	0,64	2,77	0,53	0,65	1,76	1,08	6,20	8,59	0,00	7,72	20,63	27,39	639	
Small intestine	0,00	0,00	0,00	0,00	0,00	0,64	0,00	0,00	0,00	0,00	0,00	0,00	1,43	0,00	0,00	0,00	0,00	9662	
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,66	0,00	3,53	6,48	6,20	15,75	7,28	7,72	16,50	20,54	404	
Testis	0,00	0,65	0,00	0,67	0,00	2,57	2,21	1,06	2,60	0,00	1,08	0,00	1,43	0,00	0,00	0,00	0,00	1630	
Thyroid	0,00	0,00	0,00	0,00	0,73	0,00	0,00	0,00	0,00	0,00	1,08	0,00	4,30	1,82	5,15	0,00	13,70	1530	
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,76	1,08	1,24	4,30	12,74	0,00	0,00	0,00	947	

ASIAN MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	38,93	0,00	0,00	0,00	0,00	21,12	16,71	15,42	16,00	37,82	152,61	163,62	103,90	330,10	411,21	241,92	852,89	16
All sites but C44	38,93	0,00	0,00	0,00	0,00	21,12	16,71	15,42	16,00	37,82	152,61	163,62	103,90	330,10	342,67	241,92	852,89	17
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	68,53	0,00	0,00	292
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,91	21,80	0,00	0,00	0,00	68,53	0,00	0,00	184
Brain, CNS	38,93	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	47,16	0,00	0,00	0,00	233
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	16,71	0,00	0,00	0,00	21,80	27,27	0,00	47,16	0,00	0,00	0,00	178
Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	21,12	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	947
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34,63	0,00	0,00	0,00	284,30	578
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	21,80	0,00	0,00	0,00	0,00	0,00	0,00	918
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,00	0,00	21,80	0,00	0,00	0,00	0,00	0,00	0,00	530
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	34,63	0,00	0,00	0,00	0,00	578
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	284,30	
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	47,16	0,00	0,00	0,00	425
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	120,96	0,00	
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	18,91	0,00	0,00	0,00	0,00	0,00	0,00	284,30	1058
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	65,40	136,35	34,63	141,47	274,14	120,96	0,00	31
Testis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	15,42	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1298
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	47,16	0,00	0,00	0,00	425

**BLACK MALES**

Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	2,00	4,36	5,89	6,81	6,30	10,72	16,70	27,00	46,37	102,69	137,73	278,15	481,11	520,65	607,15	678,80	1250,01	9
All sites but C44	2,00	4,36	5,89	6,06	5,51	10,05	14,39	25,87	41,38	98,89	129,04	269,45	459,15	502,17	602,33	640,01	1250,01	10
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,25	0,71	3,80	0,00	6,95	2,20	3,08	4,82	0,00	27,78	840
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	1,24	1,74	4,39	6,16	4,82	0,00	0,00	1058
Bladder	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,00	2,85	6,20	1,74	8,79	18,48	4,82	0,00	0,00	460
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	35715
Brain, CNS	0,00	0,00	0,74	0,00	0,00	0,67	0,58	0,00	0,71	0,00	0,00	3,48	0,00	3,08	0,00	0,00	0,00	2160
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,56	0,00	1,90	3,72	1,74	4,39	0,00	9,64	0,00	0,00	912
Burkitt lymphoma	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29851
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	1,73	1,69	3,57	8,56	7,44	12,17	24,17	27,73	19,27	9,70	55,56	189
Connective tissue	0,00	0,73	0,74	0,00	0,79	0,00	0,58	1,12	2,85	0,00	1,24	0,00	0,00	0,00	0,00	0,00	0,00	2485
Endocrine	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,48	4,39	0,00	0,00	0,00	0,00	2542
Eye	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,74	2,20	0,00	0,00	0,00	27,78	5077
Haematology other	0,00	0,00	0,74	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,24	0,00	0,00	0,00	0,00	0,00	0,00	10102
Hodgkin lymphoma	0,67	1,45	0,00	1,51	0,79	0,00	1,15	1,12	2,14	0,95	0,00	0,00	2,20	0,00	0,00	0,00	0,00	1670
Ill defined	0,00	0,00	0,00	0,00	0,00	0,00	0,58	1,69	0,00	0,00	0,00	3,48	6,59	6,16	0,00	0,00	0,00	1082
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,79	0,67	1,73	2,81	1,43	5,71	3,72	12,17	2,20	0,00	9,64	9,70	0,00	490
Kidney	0,67	0,00	0,74	0,00	0,00	0,00	0,00	0,56	0,00	0,00	3,72	1,74	0,00	0,00	0,00	0,00	0,00	2692
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	1,43	0,95	0,00	5,22	13,18	9,24	4,82	0,00	0,00	565
Leukaemia	0,00	1,45	2,21	2,27	0,00	0,00	0,58	2,25	1,43	3,80	1,24	0,00	4,39	9,24	9,64	19,39	55,56	520
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,95	0,00	1,74	0,00	0,00	0,00	0,00	0,00	7435
Liver & Bile duct	0,00	0,00	0,74	0,00	0,00	0,00	1,15	0,00	2,14	0,95	2,48	0,00	4,39	0,00	4,82	0,00	0,00	1200
Lung	0,00	0,00	0,00	0,00	0,00	1,34	0,58	1,12	0,00	8,56	3,72	12,17	17,57	12,32	24,09	29,09	27,78	246
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,58	0,00	0,00	0,95	2,48	0,00	0,00	0,00	0,00	0,00	27,78	4988
Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,74	0,00	0,00	4,82	0,00	0,00	3049
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4,39	6,16	0,00	0,00	0,00	1896
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,58	1,12	0,00	2,85	2,48	1,74	4,39	0,00	0,00	0,00	0,00	1520

Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,56	0,71	2,85	1,24	3,48	8,79	0,00	9,64	0,00	0,00	716
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	1,34	1,15	1,69	7,13	11,41	6,20	6,95	8,79	6,16	0,00	0,00	0,00	394
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,56	2,14	0,00	6,20	12,17	17,57	15,40	4,82	19,39	0,00	340
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1,43	2,85	2,48	5,22	2,20	0,00	0,00	9,70	0,00	1411
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,71	0,95	1,24	5,22	0,00	3,08	0,00	0,00	0,00	1786
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	3,57	4,75	8,69	6,95	6,59	6,16	24,09	19,39	0,00	329
Primary site unknown	0,67	0,00	0,00	0,76	0,00	0,00	0,00	1,69	2,85	3,80	1,24	15,65	21,97	6,16	28,91	9,70	0,00	239
Prostate	0,00	0,00	0,00	0,76	2,36	2,01	2,30	2,25	6,42	25,67	53,35	133,86	270,21	351,21	438,50	504,25	944,45	16
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	4,28	2,85	6,20	3,48	10,98	12,32	0,00	9,70	0,00	499
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,48	1,74	0,00	3,08	0,00	0,00	0,00	2740
Skin other	0,00	0,00	0,00	0,76	0,79	0,67	2,30	0,56	0,71	0,95	1,24	3,48	6,59	0,00	0,00	29,09	0,00	1109
Small intestine	0,00	0,00	0,00	0,00	0,00	0,67	0,00	0,00	0,00	0,00	0,00	0,00	2,20	0,00	0,00	0,00	0,00	6969
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,25	0,00	2,85	6,20	5,22	10,98	6,16	0,00	9,70	83,33	595
Testis	0,00	0,73	0,00	0,76	0,00	1,34	0,58	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	5866
Thyroid	0,00	0,00	0,00	0,00	0,79	0,00	0,00	0,00	0,00	0,00	0,00	0,00	2,20	3,08	0,00	0,00	0,00	3295
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,95	0,00	1,74	2,20	6,16	0,00	0,00	0,00	1810

COLOURED MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,31	8,39	34,67	39,63	72,22	125,26	206,62	301,31	455,65	41
All sites but C44	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,31	8,39	34,67	39,63	72,22	107,37	177,10	241,05	151,88	45
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,89	29,52	60,26	151,88	422
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	17,89	0,00	0,00	0,00	1118
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,39	8,67	9,91	0,00	0,00	29,52	0,00	0,00	355
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	0,00	0,00	0,00	0,00	0,00	0,00	2307
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29,52	0,00	0,00	678
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,04	0,00	0,00	0,00	0,00	1662
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,91	0,00	17,89	0,00	120,53	0,00	720
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	0,00	0,00	17,89	0,00	0,00	0,00	754
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,04	0,00	0,00	0,00	0,00	1662
Naso-Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,04	0,00	0,00	0,00	0,00	1662
Non Hodgkin lymphoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	29,52	0,00	0,00	678
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,04	0,00	0,00	0,00	0,00	1662
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,91	0,00	0,00	0,00	60,26	151,88	2019
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,31	0,00	0,00	9,91	12,04	53,68	88,55	60,26	0,00	117
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	151,88	
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	12,04	0,00	0,00	0,00	0,00	1662
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	0,00	0,00	0,00	0,00	0,00	0,00	2307

WHITE MALES																		
Site	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+	LR74
All sites	0,00	33,30	14,20	13,61	13,53	59,09	72,53	87,99	138,67	193,72	338,78	623,25	927,51	1191,00	1709,97	1564,76	1881,21	4
All sites but C44	0,00	33,30	14,20	13,61	13,53	59,09	62,17	87,99	138,67	185,30	309,32	565,84	873,48	1122,10	1534,29	1352,08	1590,07	5
Anus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,84	0,00	0,00	0,00	2033
BCC	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,73	16,40	27,01	49,21	35,14	106,34	134,37	141
Bladder	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	22,09	16,40	36,02	19,69	11,71	0,00	67,19	189
Bone	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,00	0,00	0,00	0,00	0,00	2223
Brain, CNS	0,00	0,00	0,00	0,00	13,53	11,82	0,00	8,80	8,67	0,00	14,73	0,00	0,00	9,84	11,71	15,19	22,40	253
Breast	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	27,01	19,69	11,71	0,00	0,00	343
Colorectal	0,00	0,00	0,00	0,00	0,00	0,00	10,36	26,40	8,67	33,69	36,82	90,21	99,05	196,86	152,26	182,30	134,37	31
Connective tissue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,42	14,73	0,00	0,00	9,84	0,00	15,19	0,00	607
Endocrine	0,00	16,65	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	1202
Haematology other	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,42	0,00	8,20	0,00	0,00	11,71	30,38	22,40	706
Hodgkin lymphoma	0,00	0,00	0,00	13,61	0,00	0,00	10,36	0,00	0,00	8,42	0,00	0,00	0,00	0,00	23,42	0,00	0,00	359
Ill defined	0,00	0,00	14,20	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,20	9,00	9,84	11,71	15,19	0,00	378
Kaposi Sarcoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	11,71	0,00	0,00	1708
Kidney	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,36	0,00	36,02	0,00	35,14	15,19	22,40	255
Larynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,20	36,02	0,00	0,00	0,00	0,00	453
Leukaemia	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,36	8,20	18,01	9,84	35,14	45,58	0,00	255
Lip	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,20	0,00	0,00	0,00	0,00	0,00	2440
Liver & Bile duct	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,42	0,00	8,20	27,01	29,53	11,71	30,38	22,40	236
Lung	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,80	0,00	0,00	7,36	24,60	45,02	39,37	81,99	30,38	111,98	97
Melanoma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,80	17,33	16,85	36,82	41,00	72,04	39,37	70,27	91,15	156,77	67

Mesothelioma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	9,84	35,14	15,19	0,00	445
Mouth	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,20	9,00	0,00	11,71	0,00	0,00	692	
Myeloma	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	0,00	7,36	0,00	9,00	19,69	11,71	30,38	22,40	355	
Naso- Oropharynx	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,40	9,00	19,69	0,00	15,19	44,79	444	
Non Hodgkin lymphoma	0,00	16,65	0,00	0,00	0,00	23,64	0,00	0,00	26,00	8,42	14,73	0,00	0,00	19,69	35,14	45,58	0,00	139	
Oesophagus	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	8,42	7,36	24,60	18,01	9,84	11,71	30,38	0,00	226	
Other specified	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	16,40	18,01	9,84	0,00	45,58	0,00	452	
Pancreas	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	0,00	7,36	24,60	18,01	19,69	23,42	60,77	22,40	197	
Penis	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	0,00	7,36	0,00	9,00	9,84	0,00	0,00	0,00	574	
Primary site unknown	0,00	0,00	0,00	0,00	0,00	0,00	10,36	17,60	0,00	42,11	22,09	16,40	27,01	29,53	105,41	15,19	134,37	74	
Prostate	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	25,27	73,65	221,42	234,13	521,68	773,00	546,91	739,05	11	
SCC of skin	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	14,73	16,40	0,00	19,69	93,70	75,96	67,19	139	
Salivary gland	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,67	0,00	0,00	0,00	18,01	0,00	0,00	30,38	22,40	750	
Skin other	0,00	0,00	0,00	0,00	0,00	0,00	10,36	0,00	0,00	8,42	0,00	24,60	27,01	0,00	35,14	30,38	89,58	190	
Stomach	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,80	0,00	8,42	7,36	16,40	54,03	19,69	35,14	45,58	0,00	134	
Testis	0,00	0,00	0,00	0,00	0,00	23,64	31,09	8,80	34,67	0,00	7,36	0,00	9,00	0,00	0,00	0,00	0,00	175	
Thyroid	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	7,36	0,00	9,00	0,00	23,42	0,00	44,79	503	
Tongue	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	0,00	8,42	0,00	0,00	18,01	39,37	0,00	0,00	0,00	304	

## Frequency of Cancer by Age Group

ALL FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	2848	0	6	4	6	8	17	59	126	258	324	352	319	325	293	277	235	124	115
All sites but C44	2762	0	6	4	6	8	16	58	124	249	316	345	312	318	290	267	230	120	93
Anus	36	0	0	0	0	0	0	0	2	3	7	5	5	2	2	2	2	6	0
BCC	30	0	0	0	0	0	0	0	1	2	2	3	5	2	1	3	3	2	6
Bladder	20	0	0	0	0	0	0	0	1	1	3	1	0	1	2	4	3	1	3
Bone	6	0	0	0	0	0	0	1	0	1	0	1	0	1	0	1	0	1	0
Brain, CNS	18	0	1	3	0	0	0	0	1	0	0	3	3	2	3	2	0	0	0
Breast	782	0	0	0	0	0	3	17	31	71	79	108	101	83	91	64	75	36	23
Cervix	799	0	0	0	0	0	1	9	37	102	133	130	103	109	61	52	39	17	6
Colorectal	152	0	0	0	0	1	1	5	8	9	7	11	13	13	29	24	16	6	9
Connective tissue	17	0	0	1	1	0	0	2	0	3	0	3	1	0	1	3	0	0	2
Endocrine	6	0	0	0	1	0	1	0	0	0	1	0	0	2	0	0	0	0	1
Eye	7	0	0	0	0	1	0	1	1	0	0	1	0	0	2	1	0	0	0
Haematology other	13	0	1	0	0	0	0	0	0	0	0	2	0	1	2	1	3	1	2
Hodgkin lymphoma	15	0	0	0	0	2	4	2	0	0	4	2	0	0	0	0	1	0	0
Ill defined	15	0	0	0	0	0	0	1	0	3	0	2	2	2	1	2	2	0	0
Kaposi Sarcoma	21	0	0	0	0	0	0	1	9	1	3	2	2	1	1	0	0	1	0
Kidney	8	0	0	0	1	0	0	0	0	0	0	1	0	3	1	0	2	0	0
Larynx	8	0	0	0	0	0	0	0	0	0	0	1	4	0	1	2	0	0	0
Leukaemia	35	0	1	0	2	2	0	0	3	2	5	1	0	1	2	5	4	2	5

Lip	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Liver & Bile duct	21	0	0	0	0	0	0	0	0	0	1	0	4	1	3	3	5	1	3
Lung	43	0	0	0	0	0	0	1	0	0	1	3	3	5	6	6	7	6	5
Melanoma	38	0	2	0	0	0	0	0	1	5	1	2	3	4	3	6	3	5	3
Mesothelioma	12	0	0	0	0	0	0	0	0	0	0	0	0	1	0	5	2	4	0
Mouth	5	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	1	0	1
Myeloma	19	0	0	0	0	0	0	0	0	0	0	2	1	3	5	4	2	1	1
Naso-Oropharynx	9	0	0	0	0	0	0	0	0	0	5	0	0	0	3	1	0	0	0
Non Hodgkin lymphoma	71	0	0	0	0	1	2	6	8	5	7	8	6	5	6	7	3	1	6
Oesophagus	32	0	0	0	0	0	0	0	0	2	2	4	2	4	5	4	4	1	4
Other specified	28	0	0	0	0	0	0	0	1	4	1	3	3	2	3	6	2	2	1
Ovary	49	0	0	0	0	0	1	0	5	2	4	6	5	3	8	9	1	3	2
Pancreas	17	0	0	0	0	0	0	1	0	0	1	1	0	1	1	7	3	1	1
Placenta	4	1	0	0	0	0	0	1	0	1	2	0	0	0	0	0	0	0	0
Primary site unknown	128	0	1	0	1	1	1	3	2	9	11	13	16	20	13	14	10	8	5
SCC of skin	39	0	0	0	0	0	0	0	1	6	6	3	2	3	2	4	0	2	10
Salivary gland	6	0	0	0	0	0	0	0	1	0	0	0	1	1	1	0	1	1	0
Skin other	16	0	0	0	0	0	1	1	0	1	0	1	0	2	0	3	2	0	5
Small intestine	6	0	0	0	0	0	0	0	0	0	0	0	1	3	1	0	1	0	0
Stomach	23	0	0	0	0	0	0	0	1	0	1	2	4	2	5	3	3	0	2
Thyroid	24	0	0	0	0	0	0	2	3	2	4	4	2	3	1	1	2	0	0
Tongue	7	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	2	0	0
Uterus	138	0	0	0	0	0	0	3	2	3	5	1	7	28	23	22	28	12	4
Vagina	14	0	0	0	0	0	0	1	0	1	2	2	1	2	0	0	2	1	2
Vulva	110	0	0	0	0	0	2	1	7	18	26	19	17	7	3	4	1	2	3

ASIAN FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	50	0	0	0	0	0	0	2	1	10	0	7	4	6	5	3	7	2	3
All sites but C44	49	0	0	0	0	0	0	2	1	10	0	7	4	6	5	3	7	2	2
Anus	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Bladder	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Breast	26	0	0	0	0	0	0	1	1	5	0	6	0	5	1	3	3	1	0
Cervix	3	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0	0	0	0
Colorectal	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	0
Lung	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Ovary	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	1
Pancreas	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Primary site unknown	2	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	0
SCC of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Stomach	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0

BLACK FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	1982	0	6	3	6	8	16	46	106	211	282	281	234	232	175	164	120	66	6
All sites but C44	1948	0	6	3	6	8	15	46	105	203	276	278	231	230	174	157	119	66	6
Anus	33	0	0	0	0	0	0	0	2	2	6	5	5	2	2	2	1	6	0
BCC	9	0	0	0	0	0	0	0	0	2	1	1	2	0	0	2	1	0	0
Bladder	9	0	0	0	0	0	0	0	1	0	3	1	0	1	0	3	0	0	0
Bone	5	0	0	0	0	0	0	1	0	1	0	1	0	1	0	0	0	1	0
Brain, CNS	10	0	1	2	0	0	0	0	0	0	0	2	2	1	1	1	0	0	1
Breast	457	0	0	0	0	0	3	13	25	53	65	71	62	48	46	23	26	17	0
Cervix	720	0	0	0	0	0	1	8	36	91	119	120	96	97	53	47	33	15	0
Colorectal	78	0	0	0	0	1	1	3	6	8	6	7	6	8	13	12	4	2	0
Connective tissue	12	0	0	1	1	0	0	2	0	2	0	2	1	0	1	2	0	0	0
Endocrine	5	0	0	0	1	0	1	0	0	0	1	0	0	2	0	0	0	0	0
Eye	5	0	0	0	0	1	0	1	1	0	0	1	0	0	1	0	0	0	0
Haematology other	3	0	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	1
Hodgkin lymphoma	13	0	0	0	0	2	4	1	0	0	4	2	0	0	0	0	0	0	0
Ill defined	12	0	0	0	0	0	0	1	0	3	0	2	1	0	1	2	2	0	0
Kaposi Sarcoma	18	0	0	0	0	0	0	1	8	0	3	2	1	1	1	0	0	1	0
Kidney	4	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	1	0	0
Larynx	5	0	0	0	0	0	0	0	0	0	0	1	3	0	0	1	0	0	0
Leukaemia	21	0	1	0	2	2	0	0	3	2	4	1	0	1	2	2	1	0	1

Lip	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Liver & Bile duct	7	0	0	0	0	0	0	0	0	0	0	0	1	1	2	2	1	0	0
Lung	11	0	0	0	0	0	0	1	0	0	1	3	1	2	0	1	0	2	0
Melanoma	10	0	2	0	0	0	0	0	0	2	0	1	1	0	0	0	0	2	2
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0
Mouth	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0
Myeloma	11	0	0	0	0	0	0	0	0	0	0	1	1	3	3	1	2	0	0
Naso-Oropharynx	9	0	0	0	0	0	0	0	0	0	5	0	0	0	3	1	0	0	0
Non Hodgkin lymphoma	54	0	0	0	0	1	2	6	8	5	7	7	4	3	6	4	0	1	0
Oesophagus	25	0	0	0	0	0	0	0	0	2	1	2	2	4	2	3	4	1	0
Other specified	20	0	0	0	0	0	0	0	1	2	1	3	2	2	2	4	1	1	0
Ovary	19	0	0	0	0	0	0	0	3	2	4	3	2	0	0	5	0	0	0
Pancreas	9	0	0	0	0	0	0	1	0	0	1	0	0	1	0	4	1	0	0
Placenta	4	0	0	0	0	0	0	1	0	1	2	0	0	0	0	0	0	0	0
Primary site unknown	93	0	1	0	1	1	1	2	1	6	11	10	14	17	6	10	8	3	1
SCC of skin	20	0	0	0	0	0	0	0	1	6	5	2	1	1	1	3	0	0	0
Salivary gland	4	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	1	0	0
Skin other	4	0	0	0	0	0	1	0	0	0	0	0	0	1	0	2	0	0	0
Small intestine	3	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0
Stomach	11	0	0	0	0	0	0	0	0	0	1	2	1	1	3	2	1	0	0
Thyroid	12	0	0	0	0	0	0	1	1	1	1	3	1	1	1	0	2	0	0
Tongue	4	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	1	0	0
Uterus	116	0	0	0	0	0	0	1	1	3	4	1	6	20	22	20	25	10	0
Vagina	11	0	0	0	0	0	0	1	0	1	2	2	0	1	0	0	2	0	0
Vulva	98	0	0	0	0	0	2	1	7	15	24	19	14	7	2	3	1	2	1

COLOURED FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	70	0	6	3	6	8	16	46	106	211	282	281	234	232	175	164	120	66	26
All sites but C44	67	0	6	3	6	8	15	46	105	203	276	278	231	230	174	157	119	66	25
BCC	1	0	0	0	0	0	0	0	2	2	6	5	5	2	2	2	1	6	0
Brain, CNS	1	0	0	0	0	0	0	0	0	2	1	1	2	0	0	2	1	0	0
Breast	27	0	0	0	0	0	0	0	1	0	3	1	0	1	0	3	0	0	0
Cervix	17	0	0	0	0	0	0	1	0	1	0	1	0	1	0	0	0	1	0
Colorectal	2	0	1	2	0	0	0	0	0	0	0	2	2	1	1	1	0	0	0
Connective tissue	1	0	0	0	0	0	3	13	25	53	65	71	62	48	46	23	26	17	5
Ill defined	2	0	0	0	0	0	1	8	36	91	119	120	96	97	53	47	33	15	4
Kaposi Sarcoma	1	0	0	0	0	1	1	3	6	8	6	7	6	8	13	12	4	2	1
Leukaemia	1	0	0	1	1	0	0	2	0	2	0	2	1	0	1	2	0	0	0
Liver & Bile duct	1	0	0	0	1	0	1	0	0	0	1	0	0	2	0	0	0	0	0
Lung	1	0	0	0	0	1	0	1	1	0	0	1	0	0	1	0	0	0	0
Melanoma	1	0	1	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	2	4	1	0	0	4	2	0	0	0	0	0	0	0
Oesophagus	2	0	0	0	0	0	0	1	0	3	0	2	1	0	1	2	2	0	0
Other specified	2	0	0	0	0	0	0	1	8	0	3	2	1	1	1	0	0	1	0
Ovary	1	0	0	0	1	0	0	0	0	0	0	1	0	1	0	0	1	0	0
Primary site unknown	1	0	0	0	0	0	0	0	0	0	0	1	3	0	0	1	0	0	0
SCC of skin	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
Thyroid	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
Uterus	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Vulva	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0

WHITE FEMALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	695	0	0	0	0	0	1	10	12	22	25	50	72	68	95	99	101	55	85
All sites but C44	648	0	0	0	0	0	1	9	11	21	24	46	68	64	94	96	97	51	66
Anus	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0
BCC	20	0	0	0	0	0	0	0	1	0	1	2	3	1	1	1	2	2	6
Bladder	10	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	3	1	3
Bone	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Brain, CNS	7	0	0	0	0	0	0	0	1	0	0	1	1	1	2	1	0	0	0
Breast	261	0	0	0	0	0	0	2	3	11	7	24	35	28	35	36	44	18	18
Cervix	45	0	0	0	0	0	0	1	0	4	8	6	6	4	6	3	3	2	2
Colorectal	67	0	0	0	0	0	0	2	1	1	1	4	7	4	13	11	11	4	8
Connective tissue	4	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	2
Endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Eye	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Haematology other	10	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	3	1	2
Hodgkin lymphoma	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0
Ill defined	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Kidney	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0
Larynx	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0
Leukaemia	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2	2	5
Liver & Bile duct	13	0	0	0	0	0	0	0	0	0	0	0	3	0	1	1	4	1	3

Lung	29	0	0	0	0	0	0	0	0	0	0	0	0	1	3	5	5	7	3	5
Melanoma	26	0	0	0	0	0	0	0	0	1	2	1	1	2	4	3	5	3	3	1
Mesothelioma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	4	1	2	0
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Myeloma	7	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	2	0	1	1
Non Hodgkin lymphoma	14	0	0	0	0	0	0	0	0	0	0	0	1	2	1	0	2	2	0	6
Oesophagus	5	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2	1	0	0	0
Other specified	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	1	1	0
Ovary	25	0	0	0	0	0	1	0	1	0	0	0	3	1	2	8	4	1	3	1
Pancreas	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	1	0
Primary site unknown	26	0	0	0	0	0	0	0	0	1	0	0	2	2	2	6	3	2	4	4
SCC of skin	15	0	0	0	0	0	0	0	0	0	0	0	1	1	2	0	1	0	2	8
Salivary gland	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
Skin other	12	0	0	0	0	0	0	1	0	1	0	1	0	1	0	1	1	2	0	5
Small intestine	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0
Stomach	10	0	0	0	0	0	0	0	1	0	0	0	0	2	1	2	1	2	0	1
Thyroid	10	0	0	0	0	0	0	1	2	1	3	0	1	2	0	0	0	0	0	0
Uterus	19	0	0	0	0	0	0	2	1	0	1	0	1	6	1	2	2	2	2	1
Vagina	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0
Vulva	5	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	2

ALL MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	2066	0	4	8	9	10	10	22	38	61	88	135	172	252	337	310	288	184	138
All sites but C44	1934	0	4	8	9	9	9	21	32	59	81	130	160	240	321	295	270	163	123
Anus	19	0	0	0	0	0	0	0	0	5	1	4	0	4	1	2	1	0	1
BCC	44	0	0	0	0	0	0	0	1	1	0	0	4	3	5	8	6	9	7
Bladder	43	0	0	0	0	0	0	1	0	0	0	4	10	4	9	9	3	0	3
Bone	2	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0
Brain, CNS	19	0	1	0	1	0	1	2	1	1	2	0	2	2	0	3	1	1	1
Breast	17	0	0	0	0	0	0	0	0	1	0	2	3	1	5	2	3	0	0
Burkitt lymphoma	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Colorectal	156	0	0	0	0	0	0	0	5	6	7	14	13	20	22	30	18	13	8
Connective tissue	16	0	0	1	1	0	1	0	1	2	4	1	3	0	0	1	0	1	0
Endocrine	5	0	0	1	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0
Eye	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1
Haematology other	9	0	0	0	1	0	0	0	0	0	0	1	2	1	0	0	1	2	1
Hodgkin lymphoma	23	0	1	2	0	3	2	1	3	2	4	2	0	0	1	0	2	0	0
Ill defined	17	0	0	0	1	0	0	0	1	3	0	0	0	3	4	3	1	1	0
Kaposi Sarcoma	34	0	0	0	0	0	1	1	3	5	2	6	3	8	1	0	3	1	0
Kidney	20	0	1	0	1	0	0	0	0	1	1	0	4	1	5	0	3	1	2
Larynx	24	0	0	0	0	0	0	0	1	0	2	1	1	4	10	3	2	0	0
Leukaemia	46	0	0	2	3	3	0	0	1	4	2	5	2	1	5	5	5	5	3

Lip	3	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0
Liver & Bile duct	27	0	0	0	1	0	0	0	2	0	4	2	3	1	6	3	2	2	1
Lung	78	0	0	0	0	0	0	2	1	3	0	9	4	11	14	9	12	7	6
Melanoma	53	0	0	0	0	0	0	0	1	1	2	3	8	5	8	5	6	6	8
Mesothelioma	7	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	4	1	0
Mouth	9	0	0	0	0	0	0	0	0	0	0	0	0	1	4	2	1	0	1
Myeloma	21	0	0	0	0	0	0	0	1	2	1	3	3	1	3	3	1	2	1
Naso-Oropharynx	24	0	0	0	0	0	0	1	0	1	1	3	1	4	6	2	2	1	2
Non Hodgkin lymphoma	64	0	0	1	0	0	0	4	2	3	14	13	7	5	4	4	4	3	0
Oesophagus	47	0	0	0	0	0	0	0	0	1	4	1	6	11	11	6	2	5	0
Other specified	20	0	0	0	0	0	0	0	0	0	2	3	2	5	3	1	0	4	0
Pancreas	23	0	0	0	0	0	0	0	0	0	2	1	2	6	2	3	2	4	1
Penis	38	0	0	0	0	0	0	0	0	0	6	5	8	4	4	3	6	2	0
Primary site unknown	84	0	1	0	0	1	0	0	1	6	4	10	4	12	13	5	16	3	8
Prostate	884	0	0	0	0	1	3	3	4	4	11	30	58	112	155	177	165	92	69
SCC of skin	51	0	0	0	0	0	0	0	0	0	6	3	7	4	5	7	8	7	4
Salivary gland	10	0	0	0	0	0	0	0	0	0	1	0	2	1	2	1	0	2	1
Skin other	36	0	0	0	0	1	1	1	5	1	1	2	1	5	6	0	3	5	4
Small intestine	2	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0
Stomach	45	0	0	0	0	0	0	0	0	5	0	4	6	5	11	4	3	4	3
Testis	18	0	0	1	0	1	0	4	4	2	4	0	1	0	1	0	0	0	0
Thyroid	10	0	0	0	0	0	1	0	0	0	0	0	1	0	3	1	2	0	2
Tongue	14	0	0	0	0	0	0	0	0	0	0	2	1	1	3	7	0	0	0

ASIAN MALES

Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	41	0	1	0	0	0	0	1	1	1	1	2	7	6	3	7	6	2	3
All sites but C44	40	0	1	0	0	0	0	1	1	1	1	2	7	6	3	7	5	2	3
BCC	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Bladder	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0
Brain, CNS	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Colorectal	4	0	0	0	0	0	0	0	1	0	0	0	1	1	0	1	0	0	0
Hodgkin lymphoma	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Kidney	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Liver & Bile duct	2	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0
Lung	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Myeloma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Primary site unknown	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1
Prostate	17	0	0	0	0	0	0	0	0	0	0	0	3	5	1	3	4	1	0
Testis	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0

BLACK MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	1200	0	3	6	8	9	8	16	29	48	65	108	111	160	219	169	126	70	45
All sites but C44	1147	0	3	6	8	8	7	15	25	46	58	104	104	155	209	163	125	66	45
Anus	17	0	0	0	0	0	0	0	0	4	1	4	0	4	1	1	1	0	1
BCC	8	0	0	0	0	0	0	0	0	1	0	0	1	1	2	2	1	0	0
Bladder	21	0	0	0	0	0	0	1	0	0	0	3	5	1	4	6	1	0	0
Bone	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Brain, CNS	7	0	0	0	1	0	0	1	1	0	1	0	0	2	0	1	0	0	0
Breast	11	0	0	0	0	0	0	0	0	1	0	2	3	1	2	0	2	0	0
Burkitt lymphoma	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Colorectal	60	0	0	0	0	0	0	0	3	3	5	9	6	7	11	9	4	1	2
Connective tissue	11	0	0	1	1	0	1	0	1	2	4	0	1	0	0	0	0	0	0
Endocrine	4	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0	0
Eye	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1
Haematology other	2	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Hodgkin lymphoma	15	0	1	2	0	2	1	0	2	2	3	1	0	0	1	0	0	0	0
Ill defined	11	0	0	0	0	0	0	0	1	3	0	0	0	2	3	2	0	0	0
Kaposi Sarcoma	32	0	0	0	0	0	1	1	3	5	2	6	3	7	1	0	2	1	0
Kidney	7	0	1	0	1	0	0	0	0	1	0	0	3	1	0	0	0	0	0
Larynx	17	0	0	0	0	0	0	0	1	0	2	1	0	3	6	3	1	0	0
Leukaemia	31	0	0	2	3	3	0	0	1	4	2	4	1	0	2	3	2	2	2
Lip	2	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0
Liver & Bile duct	12	0	0	0	1	0	0	0	2	0	3	1	2	0	2	0	1	0	0

Lung	45	0	0	0	0	0	0	2	1	2	0	9	3	7	8	4	5	3	1
Melanoma	5	0	0	0	0	0	0	0	1	0	0	1	2	0	0	0	0	0	1
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
Mouth	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0
Myeloma	11	0	0	0	0	0	0	0	1	2	0	3	2	1	2	0	0	0	0
Naso-Oropharynx	15	0	0	0	0	0	0	1	0	1	1	3	1	2	4	0	2	0	0
Non Hodgkin lymphoma	44	0	0	0	0	0	0	2	2	3	10	12	5	4	4	2	0	0	0
Oesophagus	32	0	0	0	0	0	0	0	0	1	3	0	5	7	8	5	1	2	0
Other specified	12	0	0	0	0	0	0	0	0	0	2	3	2	3	1	0	0	1	0
Pancreas	7	0	0	0	0	0	0	0	0	0	1	1	1	3	0	1	0	0	0
Penis	33	0	0	0	0	0	0	0	0	0	5	5	7	4	3	2	5	2	0
Primary site unknown	42	0	1	0	0	1	0	0	0	3	4	4	1	9	10	2	6	1	0
Prostate	585	0	0	0	0	1	3	3	4	4	9	27	43	77	123	114	91	52	34
SCC of skin	26	0	0	0	0	0	0	0	0	0	6	3	5	2	5	4	0	1	0
Salivary gland	4	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0	0	0
Skin other	19	0	0	0	0	1	1	1	4	1	1	1	1	2	3	0	0	3	0
Small intestine	2	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0
Stomach	26	0	0	0	0	0	0	0	0	4	0	3	5	3	5	2	0	1	3
Testis	5	0	0	1	0	1	0	2	1	0	0	0	0	0	0	0	0	0	0
Thyroid	3		0	0	0	0	1	0	0	0	0	0	0	0	1	1	0	0	0
Tongue	2	0	0	0	0	0	0	0	0	0	0	1	0	1	1	2	0	0	0

COLOURED MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	38	0	0	0	0	0	0	0	0	0	1	1	4	4	6	7	7	5	3
All sites but C44	33	0	0	0	0	0	0	0	0	0	1	1	4	4	6	6	6	4	1
BCC	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1
Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Colorectal	4	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	1	0	0
Haematology other	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Liver & Bile duct	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Lung	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0
Melanoma	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
Mouth	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Naso-Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Non Hodgkin lymphoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Oesophagus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Primary site unknown	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1
Prostate	10	0	0	0	0	0	0	0	0	0	1	0	0	1	1	3	3	1	0
SCC of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Thyroid	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Tongue	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0

WHITE MALES																			
Site	All Ages	Unknown Ages	0-4	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80+
All sites	745	0	0	2	1	1	1	5	7	10	16	23	46	76	103	121	146	103	84
All sites but C44	677	0	0	2	1	1	1	5	6	10	16	22	42	69	97	114	131	89	71
Anus	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
BCC	28	0	0	0	0	0	0	0	0	0	0	0	2	2	3	5	3	7	6
Bladder	15	0	0	0	0	0	0	0	0	0	0	0	3	2	4	2	1	0	3
Bone	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Brain, CNS	10	0	0	0	0	0	1	1	0	1	1	0	2	0	0	1	1	1	1
Breast	6	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2	1	0	0
Colorectal	87	0	0	0	0	0	0	0	1	3	1	4	5	11	11	20	13	12	6
Connective tissue	5	0	0	0	0	0	0	0	0	0	0	1	2	0	0	1	0	1	0
Endocrine	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Haematology other	6	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	2	1
Hodgkin lymphoma	5	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0	2	0	0
Ill defined	6	0	0	0	1	0	0	0	0	0	0	0	0	1	1	1	1	1	0
Kaposi Sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Kidney	10	0	0	0	0	0	0	0	0	0	0	0	1	0	4	0	3	1	1
Larynx	5	0	0	0	0	0	0	0	0	0	0	0	0	1	4	0	0	0	0
Leukaemia	11	0	0	0	0	0	0	0	0	0	0	0	1	1	2	1	3	3	0
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Liver & Bile duct	12	0	0	0	0	0	0	0	0	0	0	1	0	1	3	3	1	2	1

Lung	28	0	0	0	0	0	0	0	0	0	1	0	0	1	3	5	4	7	2	5
Melanoma	46	0	0	0	0	0	0	0	0	0	1	2	2	5	5	8	4	6	6	7
Mesothelioma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1	0
Mouth	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0	0
Myeloma	9	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	2	1	2	1
Naso-Oropharynx	8	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	2	0	1	2
Non Hodgkin lymphoma	17	0	0	1	0	0	0	2	0	0	3	1	2	0	0	2	3	3	3	0
Oesophagus	12	0	0	0	0	0	0	0	0	0	0	1	1	1	3	2	1	1	2	0
Other specified	8	0	0	0	0	0	0	0	0	0	0	0	0	0	2	2	1	0	3	0
Pancreas	16	0	0	0	0	0	0	0	0	0	0	1	0	1	3	2	2	2	4	1
Penis	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	1	0	0	0
Primary site unknown	35	0	0	0	0	0	0	0	1	2	0	5	3	2	3	3	9	1	6	
Prostate	254	0	0	0	0	0	0	0	0	0	0	3	10	27	26	53	66	36	33	
SCC of skin	22	0	0	0	0	0	0	0	0	0	0	0	2	2	0	2	8	5	3	
Salivary gland	6	0	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	0	2	1
Skin other	17	0	0	0	0	0	0	0	1	0	0	1	0	3	3	0	3	2	4	
Stomach	19	0	0	0	0	0	0	0	0	1	0	1	1	2	6	2	3	3	0	
Testis	12	0	0	0	0	0	0	2	3	1	4	0	1	0	1	0	0	0	0	0
Thyroid	6	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	0	2	
Tongue	7	0	0	0	0	0	0	0	0	0	0	1	0	0	2	4	0	0	0	